Chemically modified RNAi constructs and uses thereof

Through chemical modification and the design of internucleotide bonds of phosphorothioate, the in vivo stability and gene silencing effect of RNAi constructs are improved, and the problem of insufficient gene silencing activity and duration of existing RNAi therapies in vivo is solved, and the problem of insufficient gene silencing activity and duration of existing RNAi therapies is achieved. Effective inhibition of target gene expression.

CN119061010APending Publication Date: 2024-12-03AMGEN INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410832977.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-12-10
Filing Date
2019-12-09
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing RNAi therapies have insufficient gene silencing activity and duration in the body, making it difficult to effectively inhibit target gene expression and affect the therapeutic effect.

Method used

A chemically modified RNAi construct is designed, including specific nucleotide modification patterns and phosphorothioate internucleotide bonds, to improve the in vivo stability and gene silencing efficacy of RNAi constructs, suitable for a variety of Target and sequence.

Benefits of technology

It significantly improves the gene silencing activity and duration of RNAi constructs in vivo, enhances the inhibitory effect on target gene expression, and provides a feasible therapeutic solution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The present invention relates to chemically modified RNAi constructs and uses thereof. The present invention relates to chemically modified RNAi constructs for reducing expression of a target gene. In particular, the present invention relates to specific patterns of modified nucleotides incorporating RNAi constructs to improve in vivo stability and effectiveness. Also described are pharmaceutical compositions comprising the chemically modified RNAi constructs and methods of inhibiting expression of a target gene in vivo, e.g., to treat or ameliorate a variety of disease conditions, by administering the chemically modified RNAi constructs.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 777,677, filed December 10, 2018, which is incorporated herein by reference in its entirety.

[0003] Instructions for electronically submitting text files

[0004] This application contains a sequence listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. A computer-readable format copy of the sequence listing created on December 9, 2019 is named A-2327-WO-PCT_SeqList_ST25 and is 24.7 kilobytes in size. Technical Field

[0005] The present invention relates to chemically modified RNAi constructs for reducing the in vivo expression of target genes. In particular, the present invention relates to specific patterns of modified nucleotides that confer improved efficacy and stability to RNAi constructs in vivo. Such RNAi constructs can be used to inhibit target gene expression to achieve therapeutic purposes. Background Art

[0006] RNA interference (RNAi) is a post-transcriptional gene silencing mechanism found in almost all phyla and is considered an evolutionarily conserved cellular defense mechanism (Fire et al., Nature, Vol. 391: 806-811, 1998; Fire et al., Trends Genet, Vol. 15: 358-363, 1999; and Hamilton and Baulcombe, Science, Vol. 286: 950-952, 1999). Physiologically, the RNAi mechanism is initiated by the Dicer enzyme-mediated generation of 18-25 base pair duplexes from longer noncoding RNAs. These short RNA molecules are loaded into an RNA-induced silencing complex (RISC), where the sense strand or passenger strand is discarded and the antisense strand or guide strand is hybridized to a fully or partially complementary mRNA sequence (Nakanishi, Wiley Interdiscip. Rev. RNA [Wiley Interdisciplinary Review RNA], Vol. 7: 637-660, 2016). The silencing of the mRNA is then induced via Ago2-mediated degradation or translation inhibition (Bobbin and Rossi, Annu. Rev. Pharmacol. Toxicol. [Annual Review of Pharmacology and Toxicology], Vol. 56: 103-122, 2016).

[0007] Advances in RNAi technology and delivery methods have led to more and more positive results for RNAi-based therapies. Such therapies represent a promising class of therapeutic agents, especially for targets that are considered "undruggable" by small molecules or biological methods. Although great progress has been made in overcoming the inherent metabolic problems of natural RNA by chemically modified development and improved delivery methods, there is still a need in the art for RNAi agents with enhanced in vivo efficacy and stability that are suitable for use for therapeutic purposes. Summary of the invention

[0008] The present invention is based in part on the design of chemical modification patterns for RNAi constructs, which improve the effectiveness and / or duration of the in vivo gene silencing activity of the construct. The modification patterns described herein can be generally applied to a variety of RNAi constructs with different sequences and targets. RNAi constructs can be used to inhibit target gene expression in vivo, for example to achieve therapeutic purposes.

[0009] Therefore, the present invention provides RNAi constructs for inhibiting the expression of target gene sequences, wherein these RNAi constructs comprise a sense strand and an antisense strand, wherein the antisense strand comprises a sequence complementary to the target gene sequence and the sense strand comprises a sequence fully complementary to the sequence of the antisense strand to form a duplex region, wherein these RNAi constructs comprise a structure represented by any one of the formulas described herein. In certain embodiments, the RNAi constructs of the present invention have a chemical modification pattern selected from one of the patterns designated as P1 to P30 as described herein.

[0010] In some embodiments, the RNAi construct comprises a structure represented by formula (A):

[0011]

[0012] In formula (A), the top strand listed in the 5' to 3' direction is the sense strand and the bottom strand listed in the 3' to 5' direction is the antisense strand; each N F represents a 2′-fluorine-modified nucleotide; each N M independently represents a modified nucleotide selected from the group consisting of a 2′-fluoro modified nucleotide, a 2′-O-methyl modified nucleotide, a 2′-O-methoxyethyl modified nucleotide, a 2′-O-alkyl modified nucleotide, a 2′-O-allyl modified nucleotide, a bicyclic nucleic acid (BNA), and a deoxyribonucleotide; each N L N independently represents a modified nucleotide selected from the group consisting of a 2′-O-methyl modified nucleotide, a 2′-O-methoxyethyl modified nucleotide, a 2′-O-alkyl modified nucleotide, a 2′-O-allyl modified nucleotide, BNA, and a deoxyribonucleotide; and N Trepresents a modified nucleotide selected from the group consisting of abasic nucleotides, inverted abasic nucleotides, inverted deoxyribonucleotides, 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs, and deoxyribonucleotides. X may be an integer from 0 to 4, provided that when x is 1, 2, 3, or 4, these N A One or more of the nucleotides are modified nucleotides independently selected from the group consisting of abasic nucleotides, inverted abasic nucleotides, inverted deoxyribonucleotides, 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs, and deoxyribonucleotides. A One or more of the nucleotides may be complementary to the nucleotides in the antisense strand. Y may be an integer from 0 to 4, provided that when y is 1, 2, 3, or 4, one or more of the n nucleotides are modified or unmodified overhang nucleotides that do not base pair with the nucleotides in the antisense strand. Z may be an integer from 0 to 4, provided that when z is 1, 2, 3, or 4, these N B One or more of the nucleotides are modified nucleotides independently selected from the group consisting of 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs, and deoxyribonucleotides. B One or more of the nucleotides may be A Nucleotide complementarity (when N A nucleotide is present in the sense strand), or may be an overhang nucleotide that does not base pair with a nucleotide in the sense strand.

[0013] In some embodiments, the RNAi construct comprises a sense strand of 19-23 nucleotides in length and an antisense strand of 19-23 nucleotides in length, wherein the sequences of the antisense strand and the sense strand are fully complementary to each other to form a duplex region of 19-21 base pairs, wherein: the nucleotides at positions 2, 7, and 14 of the antisense strand (counted from the 5' end) are 2'-fluoro-modified nucleotides; the nucleotides at positions 8 to 11 and 13 of the sense strand paired with the antisense strand (counted from the 5' end) are 2'-fluoro-modified nucleotides; and the sense strand or the antisense strand do not have more than 7 total 2'-fluoro-modified nucleotides. The RNAi construct may have a nucleotide overhang at one or both of the 3' ends of the sense strand and the antisense strand. In certain embodiments, the RNAi construct has a nucleotide overhang at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0014] In other embodiments of the present invention, the RNAi construct comprises a structure represented by formula (D):

[0015]

[0016] In formula (D), the top strand listed in the 5' to 3' direction is the sense strand and the bottom strand listed in the 3' to 5' direction is the antisense strand; each N F represents a 2′-fluorine-modified nucleotide; each N M independently represents a modified nucleotide selected from the group consisting of a 2′-fluoro modified nucleotide, a 2′-O-methyl modified nucleotide, a 2′-O-methoxyethyl modified nucleotide, a 2′-O-alkyl modified nucleotide, a 2′-O-allyl modified nucleotide, BNA, and a deoxyribonucleotide; each N L N independently represents a modified nucleotide selected from the group consisting of a 2′-O-methyl modified nucleotide, a 2′-O-methoxyethyl modified nucleotide, a 2′-O-alkyl modified nucleotide, a 2′-O-allyl modified nucleotide, BNA, and a deoxyribonucleotide; and N T represents a modified nucleotide selected from the group consisting of abasic nucleotides, inverted abasic nucleotides, inverted deoxyribonucleotides, 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs, and deoxyribonucleotides. X may be an integer from 0 to 4, provided that when x is 1, 2, 3, or 4, these N A One or more of the nucleotides are modified nucleotides independently selected from the group consisting of abasic nucleotides, inverted abasic nucleotides, inverted deoxyribonucleotides, 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs, and deoxyribonucleotides. A One or more of the nucleotides may be complementary to the nucleotides in the antisense strand. Y may be an integer from 0 to 4, provided that when y is 1, 2, 3, or 4, one or more of the n nucleotides are modified or unmodified overhang nucleotides that do not base pair with the nucleotides in the antisense strand. Z may be an integer from 0 to 4, provided that when z is 1, 2, 3, or 4, these N B One or more of the nucleotides are modified nucleotides independently selected from the group consisting of 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs, and deoxyribonucleotides. B One or more of the nucleotides may be A Nucleotide complementarity (when NA nucleotide is present in the sense strand), or may be an overhang nucleotide that does not base pair with a nucleotide in the sense strand.

[0017] In some embodiments of the present invention, the RNAi construct comprises a sense strand of 19-23 nucleotides in length and an antisense strand of 19-23 nucleotides in length, wherein the sequences of the antisense strand and the sense strand are fully complementary to each other to form a duplex region of 19-21 base pairs, wherein: the nucleotides at positions 2, 14, and 16 of the antisense strand (counted from the 5' end) are 2'-fluoro-modified nucleotides; the nucleotides at positions 10 to 13 of the sense strand that are paired with the antisense strand (counted from the 5' end) are 2'-fluoro-modified nucleotides; and neither the sense strand nor the antisense strand has more than 7 total 2'-fluoro-modified nucleotides. The RNAi construct may have a nucleotide overhang at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand. Alternatively, the RNAi construct may have a nucleotide overhang at the 3' end of both the sense strand and the antisense strand.

[0018] The RNAi constructs of the present invention may include at least one backbone modification, such as a modified internucleotide bond or internucleoside bond. In certain embodiments, the RNAi constructs described herein include at least one phosphorothioate internucleotide bond. In specific embodiments, the phosphorothioate internucleotide bond may be located at the 3′ or 5′ end of the sense strand and / or antisense strand.

[0019] The RNAi construct may further include a ligand to promote the delivery or uptake of the RNAi construct to specific tissues or cells (such as hepatocytes). In certain embodiments, the ligand-targeted RNAi construct is delivered to hepatocytes. In these and other embodiments, the ligand may include galactose, galactosamine or N-acetyl-galactosamine (GalNAc). In certain embodiments, the ligand includes a multivalent galactose or multivalent GalNAc moiety, such as a trivalent or tetravalent galactose or GalNAc moiety. The ligand may optionally be covalently attached to the 5' or 3' end of the RNAi construct sense strand by a joint. In certain embodiments, these RNAi constructs include a ligand and a joint with a structure according to any one of formulas I to IX as described herein. In one embodiment, these RNAi constructs include a ligand and a joint with a structure according to formula VI. In another embodiment, these RNAi constructs include a ligand and a joint with a structure according to formula VII. In yet another embodiment, these RNAi constructs include a ligand and a joint with a structure according to formula IX.

[0020] The present invention also provides a pharmaceutical composition comprising one of the RNAi constructs described herein and a pharmaceutically acceptable carrier, excipient and / or diluent. Such pharmaceutical compositions are particularly suitable for reducing or inhibiting the expression of a target gene in a subject's cells (e.g., hepatocytes), particularly when the overexpression of the target gene product in the subject is associated with a pathological phenotype.

[0021] The present invention includes methods for reducing or inhibiting the expression of a target gene in a cell, tissue or subject. In one embodiment, these methods include contacting a cell or tissue with one of the RNAi constructs described herein. The cell or tissue can be in vitro or in vivo. In another embodiment, these methods include administering one of the RNAi constructs described herein to a subject. The RNAi construct can be administered parenterally (e.g., intravenously or subcutaneously) to a subject. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 Several representative embodiments of RNAi construct chemical modification patterns are shown. In each schematic diagram, the upper chain represents the sense strand in the 5' to 3' direction and the lower chain represents the antisense strand in the 3' to 5' direction. The solid black circle represents the nucleotide modified by 2'-O-methyl (2'-OMe), the striped ring represents the nucleotide modified by 2'-fluorine (2'-F) and the white ring represents the reverse abasic nucleotide (invAb) or the reverse deoxyribonucleotide (invdN). The light gray line connecting the circles represents the phosphodiester bond, and the black line connecting the circles represents the phosphorothioate bond. The black frame represents the assumed Ago2 cleavage site in the RNAi construct.

[0023] Figure 2 is a bar graph of human PNPLA3 variant expression levels in the liver of mice injected with AAV encoding human PNPLA3 variants and treated with 5 mg / kg subcutaneous injections of the indicated RNAi constructs with P1 or CM1 chemical modification patterns. Human PNPLA3 expression was measured by qPCR and reported as expression levels relative to vehicle-treated animals. Expression levels are shown at day 8 after RNAi construct administration.

[0024] Figure 3 Is a bar graph of human PNPLA3 variant expression levels in the liver of mice injected with AAV encoding human PNPLA3 variants and treated with 5 mg / kg subcutaneous injections of the indicated RNAi constructs with P1, P2, P3 or P4 chemical modification patterns. Human PNPLA3 expression was measured by qPCR and reported as expression levels relative to vehicle-treated animals. Expression levels are shown at day 15 after RNAi construct administration.

[0025] Figure 4A and 4Bis a line graph plotting total flux (photons / second) versus weeks after RNAi construct injection in mice that received subcutaneous injections of vehicle or 1 mg / kg ( Figure 4A ) or 3mg / kg( Figure 4B ) with the RNAi construct of P9 chemical modification pattern.Total flux represents the signal from luciferase reporter gene, and this luciferase reporter gene contains the sequence complementary with the sequence of RNAi construct, and is expressed by mouse.The reduction of total flux shows the reduction of luciferase reporter gene expression.

[0026] Figure 5 Is a bar graph of human PNPLA3 variant expression levels in the liver of mice injected with AAV encoding human PNPLA3 variants and treated with 3 mg / kg subcutaneous injections of the indicated RNAi constructs having a chemical modification pattern of P9 (duplex numbers 7318 and 8709), CM2 (duplex number 8103), CM3 (duplex number 8104), or CM4 (duplex number 8105). Human PNPLA3 expression was measured by qPCR and reported as expression levels relative to vehicle-treated animals. Expression levels are shown at day 28 after RNAi construct administration.

[0027] Figure 6 Is a bar graph of mouse ASGR1 expression levels in the liver of mice treated with 5 mg / kg subcutaneous injection of the indicated ASGR1 RNAi constructs. Mouse ASGR1 expression was measured by qPCR and reported as expression levels normalized by Gapdh expression levels. Expression levels are shown at day 4, day 8, and day 15 after administration of RNAi constructs or buffer (phosphate buffered saline, PBS).

[0028] Figure 7 It is a line graph showing the percentage change in serum Lp(a) levels relative to baseline in double transgenic mice administered 0.5 mg / kg subcutaneous injection of the indicated RNAi constructs targeting LPA. Both RNAi constructs have the same sequence and differ only in the chemical modification pattern; duplex number 3632 has a CM1 modification pattern and duplex number 3635 has a P1 modification pattern. The percentage change in Lp(a) serum levels is shown on the 14th day (D14) and the 28th day (D28) after a single subcutaneous injection of the RNAi construct. DETAILED DESCRIPTION

[0029] The present invention is based in part on the design of chemical modification patterns for RNAi constructs, which produce effective and lasting knockdown of target gene expression in vivo through a variety of sequences and targets.Compared with the therapeutic RNAi agents with alternative chemical modification patterns described previously, the chemically modified RNAi constructs described herein are shown to have improved efficacy and / or duration in terms of gene silencing activity in vivo.The modified RNAi constructs of the present invention are suitable for suppressing target gene expression in vivo, for example, for treating or alleviating a variety of disease conditions.Therefore, the present invention provides RNAi constructs that suppress the expression of target gene sequences.

[0030] As used herein, the term "RNAi construct" refers to an agent comprising an RNA molecule that can downregulate the expression of a target gene using an RNA interference mechanism when introduced into a cell. RNA interference is a process in which a nucleic acid molecule induces the cracking and degradation of a target RNA molecule (e.g., a messenger RNA or mRNA molecule) in a sequence-specific manner, such as through an RNA-induced silencing complex (RISC) pathway. In certain embodiments, an RNAi construct comprises a double-stranded RNA molecule comprising two reverse parallel strands of continuous nucleotides that are fully complementary to each other so as to hybridize to form a duplex region. "Hybridization" or "hybridization" refers to the pairing of complementary polynucleotides, typically by hydrogen bonding (e.g., Watson-Crick hydrogen bonding, Hoogsteen hydrogen bonding, or reverse Hoogsteen hydrogen bonding) between complementary bases in two polynucleotides. A strand comprising a region having a sequence that is substantially complementary to a target sequence (e.g., a target mRNA) is referred to as an "antisense strand." A "sense strand" refers to a strand comprising a region that is substantially complementary to a region of an antisense strand. In some embodiments, the sense strand may comprise a region having a sequence that is substantially identical to the target sequence.

[0031] Double-stranded RNA molecules may include chemical modifications to ribonucleotides, including modifications to the ribose, base, or backbone components of ribonucleotides, as described herein or known in the art. For the purposes of this disclosure, the term "double-stranded RNA" includes any such modifications employed in double-stranded RNA molecules (e.g., siRNA, shRNA, etc.).

[0032] As used herein, a first sequence is "complementary" to a second sequence if a polynucleotide comprising a first sequence can hybridize to a polynucleotide comprising a second sequence to form a duplex region under certain conditions (e.g., physiological conditions). Other such conditions may include moderate or stringent hybridization conditions known to those skilled in the art. If a polynucleotide comprising a first sequence base pair is paired with a polynucleotide comprising a second sequence over the entire length of one or both nucleotide sequences and without any mismatches, the first sequence is considered to be completely complementary to the second sequence (100% complementary). If a sequence is at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% complementary to a target sequence, the sequence is "substantially complementary" to the target sequence. The percentage of complementarity can be calculated by dividing the number of bases in the first sequence that are complementary to the bases at the corresponding positions in the second sequence or target sequence by the total length of the first sequence. A sequence may also be said to be substantially complementary to another sequence if there are no more than 5, 4, 3, or 2 mismatches over a 30 base pair duplex region when the two sequences are hybridized. In general, if any nucleotide overhangs as defined herein are present, the sequence of such overhangs is not considered in determining the degree of complementarity between two sequences. For example, a sense strand of 21 nucleotides in length and an antisense strand of 21 nucleotides in length that hybridize to form a 19 base pair duplex region with a 2 nucleotide overhang at the 3' end of each strand would be considered to be fully complementary as the term is used herein.

[0033] In certain embodiments, the region of the antisense strand comprises a sequence that is completely complementary to the region of the target gene sequence (e.g., target mRNA). In such embodiments, the sense strand may comprise a sequence that is completely complementary to the sequence of the antisense strand. In other such embodiments, the sense strand may comprise a sequence that is substantially complementary to the sequence of the antisense strand, such as having 1,2,3,4, or 5 mispairings in the duplex region formed by the sense strand and the antisense strand. In certain embodiments, it is preferred that any mispairing occurs in the terminal region (e.g., in 6,5,4,3, or 2 nucleotides at the 5' and / or 3' ends of the chain). In one embodiment, any mispairing in the duplex region formed by the sense strand and the antisense strand occurs in 6,5,4,3, or 2 nucleotides at the 5' ends of the antisense strand.

[0034] In certain embodiments, the sense strand and antisense strand of a double-stranded RNA can be two separate molecules that hybridize to form a duplex region that is otherwise unconnected. Such double-stranded RNA molecules formed by two separate chains are referred to as "small interfering RNA" or "short interfering RNA" (siRNA). Therefore, in some embodiments, the RNAi constructs of the present invention include siRNA.

[0035] In other embodiments, the sense strand and antisense strand that hybridize to form a duplex region can be a part of a single RNA molecule, that is, the sense strand and antisense strand are a part of the self-complementary region of a single RNA molecule. In this case, a single RNA molecule comprises a duplex region (also referred to as a stem region) and a loop region. The 3' end of the sense strand is connected to the 5' end of the antisense strand via a continuous sequence of unpaired nucleotides, which will form a loop region. The loop region typically has enough length to allow the RNA molecule to fold back onto itself, so that the antisense strand can base pair with the sense strand and form a duplex region or a stem region. The loop region can include about 3 to about 25, about 5 to about 15, or about 8 to about 12 unpaired nucleotides. This type of RNA molecule with at least partially self-complementary regions is referred to as "short hairpin RNA" (shRNA). In certain embodiments, the RNAi construct of the present invention includes shRNA. A single at least partially self-complementary RNA molecule can be about 40 nucleotides to about 100 nucleotides, about 45 nucleotides to about 85 nucleotides, or about 50 nucleotides to about 60 nucleotides in length, and comprises a duplex region and a loop region, each region having a length recited herein.

[0036] The RNAi construct of the present invention comprises a sense strand and an antisense strand, wherein the antisense strand comprises a region having a sequence that is substantially or completely complementary to a target gene sequence. A target gene sequence generally refers to a nucleic acid sequence comprising a partial or complete coding sequence of a polypeptide. The target gene sequence may also include a non-coding region, such as a 5' or 3' untranslated region (UTR). In certain embodiments, the target gene sequence is a messenger RNA (mRNA) sequence. An mRNA sequence refers to any messenger RNA sequence encoding a protein, a protein variant, or an isoform (from any species (e.g., mouse, rat, non-human primate, human)), including splice variants. In one embodiment, the target gene sequence is an mRNA sequence encoding a human protein. The target gene sequence may also be an RNA sequence other than an mRNA sequence, such as a tRNA sequence, a microRNA sequence, or a viral RNA sequence.

[0037] The region of the antisense strand of the RNAi construct can be substantially complementary or completely complementary to at least 15 consecutive nucleotides of the target gene sequence. In certain embodiments, the scope of the target region of the gene sequence of the antisense strand comprising the complementary region can be about 15 to about 30 consecutive nucleotides, about 16 to about 28 consecutive nucleotides, about 18 to about 26 consecutive nucleotides, about 17 to about 24 consecutive nucleotides, about 19 to about 30 consecutive nucleotides, about 19 to about 25 consecutive nucleotides, about 19 to about 23 consecutive nucleotides or about 19 to about 21 consecutive nucleotides.

[0038] The sense strand of RNAi constructs typically comprises a sequence that is fully complementary to the sequence of the antisense strand, so that the two chains hybridize under physiological conditions and form a duplex region. "Duplex region" refers to a region in two complementary or substantially complementary polynucleotides, which interact by Watson-Crick base pairing or other hydrogen bonding to form base pairs, thereby forming a duplex between two polynucleotides. The duplex region of RNAi constructs should have enough length to allow RNAi constructs to enter RNA interference pathways, such as by engaging Dicer enzymes and / or RISC complexes. For example, in some embodiments, the length of the duplex region is about 15 to about 30 base pairs. Other lengths of the duplex region within this range are also suitable, such as about 15 to about 28 base pairs, about 15 to about 26 base pairs, about 15 to about 24 base pairs, about 15 to about 22 base pairs, about 17 to about 28 base pairs, about 17 to about 26 base pairs, about 17 to about 24 base pairs, about 17 to about 23 base pairs, about 17 to about 21 base pairs, about 19 to about 25 base pairs, about 19 to about 23 bases, or about 19 to about 21 base pairs. In one embodiment, the length of the duplex region is about 17 to about 24 base pairs. In another embodiment, the length of the duplex region is about 19 to about 21 base pairs. In certain embodiments, the length of the duplex region is about 19 base pairs. In other embodiments, the length of the duplex region is about 21 base pairs.

[0039] For the embodiment that the sense strand and the antisense strand are two independent molecules (for example, the RNAi construct includes siRNA), the length of the sense strand and the antisense strand need not be the same as the length of the duplex region. For example, one or both chains may be longer than the duplex region and have one or more unpaired nucleotides or mispairings on the side of the duplex region. Therefore, in some embodiments, the RNAi construct includes at least one nucleotide overhang. As used herein, "nucleotide overhang" refers to one or more unpaired nucleotides extending beyond the duplex region at the end of the chain. When the 3' end of a chain extends beyond the 5' end of another chain or when the 5' end of a chain extends beyond the 3' end of another chain, a nucleotide overhang is typically formed. The length of the nucleotide overhang is typically between 1 and 6 nucleotides, between 1 and 5 nucleotides, between 1 and 4 nucleotides, between 1 and 3 nucleotides, between 2 and 6 nucleotides, between 2 and 5 nucleotides, or between 2 and 4 nucleotides. In certain embodiments, the nucleotide overhang includes 1, 2, 3, 4, 5 or 6 nucleotides. In a specific embodiment, the nucleotide overhang includes 1 to 4 nucleotides. In certain embodiments, the nucleotide overhang comprises 2 nucleotides. In certain other embodiments, the nucleotide overhang comprises a single nucleotide.

[0040] The nucleotides in the overhang can be ribonucleotides or modified nucleotides as described herein. In some embodiments, the nucleotides in the overhang are 2'-modified nucleotides (e.g., 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides) deoxyribonucleotides, reverse nucleotides (e.g., reverse abasic nucleotides, reverse deoxyribonucleotides), or combinations thereof. For example, in one embodiment, the nucleotides in the overhang are deoxyribonucleotides, such as deoxythymidine. In another embodiment, the nucleotides in the overhang are 2'-O-methyl modified nucleotides, 2'-fluoro modified nucleotides, 2'-methoxyethyl modified nucleotides, or combinations thereof. In other embodiments, the overhang comprises 5'-uridine-uridine-3' (5'-UU-3') dinucleotides. In such embodiments, the UU dinucleotides may comprise ribonucleotides or modified nucleotides, such as 2'-modified nucleotides. In other embodiments, the overhang comprises 5'-deoxythymidine-deoxythymidine-3' (5'-dTdT-3') dinucleotides. When a nucleotide overhang is present in the antisense strand, the nucleotides in the overhang may be complementary to the target gene sequence, form a mismatch with the target gene sequence, or contain some other sequence (eg, a polypyrimidine or polypurine sequence, such as UU, TT, AA, GG, etc.).

[0041] The nucleotide overhangs may be at the 5' end or 3' end of one or both strands. For example, in one embodiment, the RNAi construct comprises nucleotide overhangs at the 5' end and the 3' end of the antisense strand. In another embodiment, the RNAi construct comprises nucleotide overhangs at the 5' end and the 3' end of the sense strand. In some embodiments, the RNAi construct comprises nucleotide overhangs at the 5' end of the sense strand and the 5' end of the antisense strand. In other embodiments, the RNAi construct comprises nucleotide overhangs at the 3' end of the sense strand and the 3' end of the antisense strand.

[0042] RNAi constructs can include nucleotide overhangs at one end of a double-stranded RNA molecule and flat ends at the other end. "Flat ends" means that the sense strand and the antisense strand are completely base paired at the ends of the molecule, and there are no unpaired nucleotides extending beyond the duplex region. In certain embodiments, the RNAi construct includes nucleotide overhangs at the 3' end of the sense strand, and includes flat ends at the 5' end of the sense strand and the 3' end of the antisense strand. In other embodiments, the RNAi construct includes nucleotide overhangs at the 3' end of the antisense strand, and includes flat ends at the 5' end of the antisense strand and the 3' end of the sense strand. In certain embodiments, the RNAi construct includes flat ends at both ends of the double-stranded RNA molecule. In such embodiments, the sense strand and the antisense strand have the same length, and the length of the duplex region is the same as the sense strand and the antisense strand (i.e., the molecule is double-stranded over its entire length).

[0043] The sense strand and antisense strand in the RNAi construct of the present invention can each independently be about 15 to about 30 nucleotides in length, about 19 to about 30 nucleotides in length, about 18 to about 28 nucleotides in length, about 19 to about 27 nucleotides in length, about 19 to about 25 nucleotides in length, about 19 to about 23 nucleotides in length, about 19 to about 21 nucleotides in length, about 21 to about 25 nucleotides in length, or about 21 to about 23 nucleotides in length. In certain embodiments, the sense strand and antisense strand are each independently about 18, about 19, about 20, about 21, about 22, about 23, about 24, or about 25 nucleotides in length. In some embodiments, the sense strand and antisense strand have the same length, but form a shorter duplex region than these strands, such that the RNAi construct has two nucleotide overhangs. For example, in one embodiment, the RNAi construct comprises (i) a sense strand and an antisense strand each having a length of 21 nucleotides, (ii) a duplex region of 19 base pairs, and (iii) a nucleotide overhang with 2 unpaired nucleotides at the 3' end of the sense strand and the 3' end of the antisense strand. In another embodiment, the RNAi construct comprises (i) a sense strand and an antisense strand each having a length of 23 nucleotides, (ii) a duplex region of 21 base pairs, and (iii) a nucleotide overhang with 2 unpaired nucleotides at the 3' end of the sense strand and the 3' end of the antisense strand. In other embodiments, the sense strand and the antisense strand have the same length, and a duplex region is formed over their entire length so that there is no nucleotide overhang at either end of the double-stranded molecule. In one such embodiment, the RNAi construct is flat-ended and comprises (i) a sense strand and an antisense strand (wherein each strand has a length of 21 nucleotides), and (ii) a duplex region of 21 base pairs in length. In another such embodiment, the RNAi construct is blunt ended and comprises (i) a sense strand and an antisense strand, wherein each strand is 23 nucleotides in length, and (ii) a duplex region that is 23 base pairs in length.

[0044] In other embodiments, the sense strand or the antisense strand is longer than the other strand and the two strands form a duplex region having a length equal to that of the shorter strand, such that the RNAi construct comprises at least one nucleotide overhang. For example, in one embodiment, the RNAi construct comprises (i) a sense strand of 19 nucleotides in length, (ii) an antisense strand of 21 nucleotides in length, (iii) a duplex region of 19 base pairs in length, and (iv) a nucleotide overhang of 2 unpaired nucleotides at the 3' end of the antisense strand. In another embodiment, the RNAi construct comprises (i) a sense strand of 21 nucleotides in length, (ii) an antisense strand of 23 nucleotides in length, (iii) a duplex region of 21 base pairs in length, and (iv) a nucleotide overhang of 2 unpaired nucleotides at the 3' end of the antisense strand.

[0045] The RNAi construct of the present invention preferably comprises modified nucleotides." modified nucleotides " refer to one or more chemically modified nucleotides with respect to nucleosides, core bases, pentose rings or phosphate groups. As used herein, modified nucleotides do not include ribonucleotides containing adenosine monophosphate, guanosine monophosphate, uridine monophosphate and cytidine monophosphate. However, the RNAi construct can comprise a combination of modified nucleotides and ribonucleotides. Modified nucleotides are incorporated into one or both chains of a double-stranded RNA molecule, and the in vivo stability of RNA molecules can be improved, for example, by reducing the sensitivity of the molecule to nucleases and other degradation processes. The effectiveness of RNAi constructs in reducing target gene expression can also be enhanced by incorporating modified nucleotides (particularly incorporating into a specific pattern as described in more detail herein).

[0046] In certain embodiments, the modified nucleotides have modifications of the ribose. These sugar modifications may include modifications at the 2' and / or 5' positions of the pentose ring, as well as bicyclic sugar modifications. 2'-modified nucleotides refer to nucleotides having a pentose ring with a substituent other than OH at the 2' position. Such 2'-modifications include, but are not limited to, 2'-H (e.g., deoxyribonucleotides), 2'-O-alkyl (e.g., O-C1-C 10 or O-C1-C 10substituted alkyl), 2'-O-allyl (O-CH2CH=CH2), 2'-C-allyl, 2'-deoxy-2'-fluoro (also known as 2'-F or 2'-fluoro), 2'-O-methyl (OCH3), 2'-O-methoxyethyl (O-(CH2)2OCH3), 2'-OCF3, 2'-O(CH2)2SCH3, 2'-O-aminoalkyl, 2'-amino (e.g., NH2), 2'-O-ethylamine, and 2'-azido. Modifications at the 5' position of the pentose ring include, but are not limited to: 5'-methyl (R or S); 5'-vinyl, and 5'-methoxy.

[0047] "Bicyclic sugar modification" refers to the modification of the pentose ring, wherein the bridge connects the two atoms of the ring to form a second ring to obtain a bicyclic sugar structure. In some embodiments, the bicyclic sugar modification comprises a bridge between the 4' and 2' carbons of the pentose ring. Nucleotides comprising a sugar moiety with a bicyclic sugar modification are referred to herein as bicyclic nucleic acids or BNAs. Exemplary bicyclic sugar modifications include, but are not limited to, α-L-methyleneoxy (4'-CH2—O-2') bicyclic nucleic acids (BNA); β-D-methyleneoxy (4'-CH2—O-2') BNA (also known as locked nucleic acids or LNA); vinyloxy (4'-(CH2)2—O-2') BNA; aminooxy (4'-CH2—O—N (R)-2') BNA; oxyamino (4'-CH2—N (R)—O-2') BNA; methyl (methyleneoxy) (4'-C H(CH3)—O-2′)BNA (also known as constrained ethyl or cEt); methylene-thio (4′-CH2—S-2′)BNA; methylene-amino (4′-CH2-N(R)-2′)BNA; methyl carbocycle (4′-CH2—CH(CH3)-2′)BNA; propylene carbocycle (4′-(CH2)3-2′)BNA; and methoxy(ethyleneoxy) (4′-CH(CH2OMe)-O-2′)BNA (also known as constrained MOE or cMOE). These and other sugar-modified nucleotides that can be incorporated into the RNAi constructs of the invention are described in U.S. Pat. No. 9,181,551, U.S. Pat. Pub. No. 2016 / 0122761, and Deleavey and Damha, Chemistry and Biology, Vol. 19: 937-954, 2012, all of which are hereby incorporated by reference in their entirety.

[0048] In some embodiments, the RNAi construct comprises one or more 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, 2'-O-methoxyethyl modified nucleotides, 2'-O-alkyl modified nucleotides, 2'-O-allyl modified nucleotides, bicyclic nucleic acids (BNAs), deoxyribonucleotides, or combinations thereof. In certain embodiments, the RNAi construct comprises one or more 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, 2'-O-methoxyethyl modified nucleotides, or combinations thereof. In certain embodiments, the RNAi construct comprises one or more 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, or combinations thereof.

[0049] Both the sense strand and the antisense strand of the RNAi construct may include one or more modified nucleotides. For example, in some embodiments, the sense strand includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more modified nucleotides. In certain embodiments, all nucleotides in the sense strand are modified nucleotides. In certain embodiments, the antisense strand includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more modified nucleotides. In other embodiments, all nucleotides in the antisense strand are modified nucleotides. In certain other embodiments, all nucleotides in the sense strand and all nucleotides in the antisense strand are modified nucleotides. In these and other embodiments, the modified nucleotides may be 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, or a combination thereof.

[0050] In certain embodiments, the modified nucleotides incorporated into one or both strands of the RNAi constructs of the invention have modifications of nucleobases (also referred to herein as "bases"). "Modified nucleobases" or "modified bases" refer to bases other than the naturally occurring purine bases adenine (A) and guanine (G) and the pyrimidine bases thymine (T), cytosine (C), and uracil (U). The modified nucleobases may be synthetic or naturally occurring modifications and include, but are not limited to, universal bases, 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine (X), hypoxanthine (I), 2-aminoadenine, 6-methyladenine, 6-methylguanine, and other alkyl derivatives of adenine and guanine, 2-propyl derivatives and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyluracil and Cytosine, 6-azouracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxy and other 8-substituted adenines and guanines, 5-halo (especially 5-bromo), 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and and 3-deazaguanine and 3-deazaadenine.

[0051] In some embodiments, the modified base is a universal base. "Universal base" refers to a base analog that forms base pairs indiscriminately with all natural bases in RNA and DNA without changing the double helix structure of the resulting duplex region. Universal bases are known to those skilled in the art, including but not limited to: inosine, C-phenyl, C-naphthyl and other aromatic derivatives, azole amides, and nitroazole derivatives (such as 3-nitropyrrole, 4-nitroindole, 5-nitroindole and 6-nitroindole).

[0052] Other suitable modified bases that can be incorporated into the RNAi constructs of the invention include those described in Herdewijn, Antisense Nucleic Acid Drug Dev., Vol. 10: 297-310, 2000 and Peacock et al., J. Org. Chem., Vol. 76: 7295-7300, 2011, which are hereby incorporated by reference in their entirety. It is well known to those skilled in the art that guanine, cytosine, adenine, thymine and uracil can be replaced by other nucleobases (such as the modified nucleobases described above) without substantially changing the base pairing properties of the polynucleotide containing nucleotides with such substituted nucleobases.

[0053] In certain embodiments, the sense strand and antisense strand of RNAi constructs can include one or more abasic nucleotides." Abasic nucleotides" or "abasic nucleosides" are nucleotides or nucleosides lacking a core base at the 1' position of ribose. In certain embodiments, abasic nucleotides are incorporated into the ends of the sense strand and / or antisense strand of RNAi constructs. In one embodiment, the sense strand includes abasic nucleotides as terminal nucleotides at its 3' end, its 5' end, or its 3' and 5' ends. In another embodiment, the antisense strand includes abasic nucleotides as terminal nucleotides at its 3' end, its 5' end, or its 3' and 5' ends. In such embodiments where abasic nucleotides are terminal nucleotides, they can be reverse nucleotides-i.e., connected to adjacent nucleotides by 3'-3' internucleotide bonds (when at the 3' end of the chain) or 5'-5' internucleotide bonds (when at the 5' end of the chain) (not natural 3'-5' internucleotide bonds). Abasic nucleotides can also include sugar modifications, such as any sugar modifications described above. In certain embodiments, the abasic nucleotide comprises a 2'-modification, such as a 2'-fluoro modification, a 2'-O-methyl modification, or a 2'-H (deoxy) modification. In one embodiment, the abasic nucleotide comprises a 2'-O-methyl modification. In another embodiment, the abasic nucleotide comprises a 2'-H modification (i.e., a deoxy abasic nucleotide).

[0054] The inventors have found that incorporating modified nucleotides into RNAi constructs according to certain patterns results in RNAi constructs with improved in vivo gene silencing activity. For example, in one embodiment, the RNAi constructs of the invention comprise a sense strand and an antisense strand containing sequences that are sufficiently complementary to each other to form a duplex region of at least 15 base pairs, wherein:

[0055] The nucleotides at positions 2, 7, and 14 of the antisense strand (counting from the 5′ end) are 2′-fluorine-modified nucleotides;

[0056] The nucleotides at the positions of the sense strand that pair with positions 8 to 11 and 13 in the antisense strand (counting from the 5′ end) are 2′-fluorine-modified nucleotides; and

[0057] • Neither the sense strand nor the antisense strand has more than 7 total 2'-fluoro modified nucleotides.

[0058] In other embodiments, the RNAi constructs of the invention comprise a sense strand and an antisense strand comprising sequences that are sufficiently complementary to each other to form a duplex region of at least 19 base pairs, wherein:

[0059] the nucleotides at positions 2, 7, and 14 of the antisense strand (counting from the 5′ end) are 2′-fluorine-modified nucleotides, the nucleotides at positions 4, 6, 10, and 12 (counting from the 5′ end) are optionally 2′-fluorine-modified nucleotides, and all other nucleotides in the antisense strand are modified nucleotides other than 2′-fluorine-modified nucleotides; and

[0060] The nucleotides at positions 8 to 11 and 13 of the sense strand that pair with the antisense strand (counting from the 5′ end) are 2′-fluorine-modified nucleotides, the nucleotides at positions 3 and 5 of the sense strand that pair with the antisense strand (counting from the 5′ end) are optionally 2′-fluorine-modified nucleotides; and all other nucleotides in the sense strand are modified nucleotides other than 2′-fluorine-modified nucleotides.

[0061] In such embodiments, the modified nucleotides other than 2'-fluoro modified nucleotides can be selected from 2'-O-methyl modified nucleotides, 2'-O-methoxyethyl modified nucleotides, 2'-O-alkyl modified nucleotides, 2'-O-allyl modified nucleotides, BNAs, and deoxyribonucleotides. In these and other embodiments, the terminal nucleotides at the 3' end, 5' end, or both the 3' end and the 5' end of the sense strand can be abasic nucleotides or deoxyribonucleotides. In such embodiments, the abasic nucleotides or deoxyribonucleotides can be reversed - i.e., connected to adjacent nucleotides by a 3'-3' internucleotide bond (when at the 3' end of the strand) or a 5'-5' internucleotide bond (when at the 5' end of the strand) (not a natural 3'-5' internucleotide bond).

[0062] In any of the above embodiments, the nucleotides at positions 2, 7, 12, and 14 of the antisense strand (counting from the 5' end) are 2'-fluorine-modified nucleotides. In other embodiments, the nucleotides at positions 2, 4, 7, 12, and 14 of the antisense strand (counting from the 5' end) are 2'-fluorine-modified nucleotides. In yet other embodiments, the nucleotides at positions 2, 4, 6, 7, 12, and 14 of the antisense strand (counting from the 5' end) are 2'-fluorine-modified nucleotides. In still other embodiments, the nucleotides at positions 2, 4, 6, 7, 10, 12, and 14 of the antisense strand (counting from the 5' end) are 2'-fluorine-modified nucleotides. In alternative embodiments, the nucleotides at positions 2, 7, 10, 12, and 14 of the antisense strand (counting from the 5' end) are 2'-fluorine-modified nucleotides. In certain other embodiments, the nucleotides at positions 2, 4, 7, 10, 12, and 14 of the antisense strand (counting from the 5' end) are 2'-fluoro modified nucleotides.

[0063] In any of the above embodiments, the nucleotides at positions 3, 8 to 11 and 13 of the sense strand that are paired with the antisense strand (counting from the 5' end) are 2'-fluoro modified nucleotides. In some embodiments, the nucleotides at positions 5, 8 to 11 and 13 of the sense strand that are paired with the antisense strand (counting from the 5' end) are 2'-fluoro modified nucleotides. In other embodiments, the nucleotides at positions 3, 5, 8 to 11 and 13 of the sense strand that are paired with the antisense strand (counting from the 5' end) are 2'-fluoro modified nucleotides.

[0064] In certain embodiments of the present invention, the RNAi construct comprises a sense strand and an antisense strand, wherein the antisense strand comprises a sequence complementary to a target gene sequence and the sense strand comprises a sequence sufficiently complementary to the sequence of the antisense strand to form a duplex region, wherein the RNAi construct comprises a structure represented by formula (A):

[0065]

[0066] in:

[0067] The top strand listed in the 5' to 3' direction is the sense strand and the bottom strand listed in the 3' to 5' direction is the antisense strand;

[0068] Each N F represents 2′-fluorine-modified nucleotides;

[0069] Each N M independently represents a modified nucleotide selected from the group consisting of 2′-fluoro-modified nucleotides, 2′-O-methyl-modified nucleotides, 2′-O-methoxyethyl-modified nucleotides, 2′-O-alkyl-modified nucleotides, 2′-O-allyl-modified nucleotides, bicyclic nucleic acids (BNAs), and deoxyribonucleotides;

[0070] Each N L independently represents a modified nucleotide selected from the group consisting of 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs and deoxyribonucleotides;

[0071] N T represents a modified nucleotide selected from the group consisting of an abasic nucleotide, an inverted abasic nucleotide, an inverted deoxyribonucleotide, a 2′-O-methyl modified nucleotide, a 2′-O-methoxyethyl modified nucleotide, a 2′-O-alkyl modified nucleotide, a 2′-O-allyl modified nucleotide, BNA and a deoxyribonucleotide;

[0072] x is an integer from 0 to 4, provided that when x is 1, 2, 3, or 4, these NA One or more of the nucleotides are modified nucleotides independently selected from the group consisting of abasic nucleotides, inverted abasic nucleotides, inverted deoxyribonucleotides, 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs, and deoxyribonucleotides, and these N A One or more of the nucleotides may be complementary to nucleotides in the antisense strand;

[0073] y is an integer from 0 to 4, provided that when y is 1, 2, 3, or 4, one or more n nucleotides are modified or unmodified overhang nucleotides that do not base pair with nucleotides in the antisense strand; and

[0074] z is an integer from 0 to 4, provided that when z is 1, 2, 3, or 4, these N B One or more of the nucleotides are modified nucleotides independently selected from the group consisting of 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs and deoxyribonucleotides, and when N A When nucleotides are present in the sense strand, these N B One or more of the nucleotides may be A Nucleotide complementarity, or these N B One or more of the nucleotides may be overhang nucleotides that do not base pair with nucleotides in the sense strand.

[0075] In some embodiments where the RNAi construct comprises a structure represented by formula (A), there is a nucleotide overhang at the 3′ end of the sense strand—that is, y is 1, 2, 3, or 4. In one such embodiment, y is 2. In embodiments where there is a 2-nucleotide overhang at the 3′ end of the sense strand (that is, y is 2), x is 0 and z is 2 or x is 1 and z is 2. In other embodiments where the RNAi construct comprises a structure represented by formula (A), the RNAi construct comprises a blunt end at the 3′ end of the sense strand and the 5′ end of the antisense strand (that is, y is 0). In such embodiments where there is no nucleotide overhang at the 3′ end of the sense strand (that is, y is 0): (i) x is 2 and z is 4, (ii) x is 3 and z is 4, (iii) x is 0 and z is 2, (iv) x is 1 and z is 2, or (v) x is 2 and z is 2. In any embodiment where x is greater than 0, N A The nucleotide (the terminal nucleotide at the 5' end of the sense strand) may be an inverted nucleotide, such as an inverted abasic nucleotide or an inverted deoxyribonucleotide.

[0076] In certain embodiments wherein the RNAi construct comprises a structure represented by formula (A), the N at positions 4 and 12 in the antisense strand, counted from the 5′ end, M are each a 2'-fluoro modified nucleotide. In other embodiments, the N at positions 4, 6, and 12 in the antisense strand, counted from the 5' end, M are each a 2'-fluoro modified nucleotide. In yet other embodiments, the N at positions 4, 6, 10, and 12 in the antisense strand, counted from the 5' end M Each is a 2'-fluoro modified nucleotide. In an alternative embodiment wherein the RNAi construct comprises a structure represented by formula (A), the N at positions 10 and 12 in the antisense strand counted from the 5' end M are each a 2'-fluoro modified nucleotide. In a related embodiment, the N at positions 4, 10, and 12 in the antisense strand, counted from the 5' end, M Each is a 2'-fluoro modified nucleotide. In other alternative embodiments wherein the RNAi construct comprises a structure represented by formula (A), the N at positions 4, 6, and 10 in the antisense strand counted from the 5' end M is a 2′-O-methyl modified nucleotide, and the N at position 12 in the antisense strand, counted from the 5′ end M is a 2'-fluoro modified nucleotide. In some embodiments wherein the RNAi construct comprises a structure represented by formula (A), each N M is a 2'-O-methyl modified nucleotide. In other embodiments, each N M is a 2'-fluoro modified nucleotide. In still other embodiments wherein the RNAi construct comprises a structure represented by formula (A), each N in both the sense strand and the antisense strand M All are 2′-O-methyl modified nucleotides.

[0077] In any of the above embodiments wherein the RNAi construct comprises a structure represented by formula (A), each N in both the sense strand and the antisense strand L can be 2'-O-methyl modified nucleotides. In these embodiments and any of the embodiments described above, N in formula (A) T It may be an inverted abasic nucleotide, an inverted deoxyribonucleotide, or a 2'-O-methyl modified nucleotide.

[0078] In certain embodiments of the present invention, the RNAi construct comprises a sense strand and an antisense strand, wherein the antisense strand comprises a sequence complementary to a target gene sequence and the sense strand comprises a sequence sufficiently complementary to the sequence of the antisense strand to form a duplex region, wherein the RNAi construct comprises a structure represented by formula (B):

[0079]

[0080] in:

[0081] The top strand listed in the 5' to 3' direction is the sense strand and the bottom strand listed in the 3' to 5' direction is the antisense strand;

[0082] Each N F represents 2′-fluorine-modified nucleotides;

[0083] Each N L independently represents a modified nucleotide selected from the group consisting of 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs and deoxyribonucleotides;

[0084] N T represents a modified nucleotide selected from the group consisting of an abasic nucleotide, an inverted abasic nucleotide, an inverted deoxyribonucleotide, a 2′-O-methyl modified nucleotide, a 2′-O-methoxyethyl modified nucleotide, a 2′-O-alkyl modified nucleotide, a 2′-O-allyl modified nucleotide, BNA and a deoxyribonucleotide;

[0085] x is an integer from 0 to 4, provided that when x is 1, 2, 3, or 4, these N A One or more of the nucleotides are modified nucleotides independently selected from the group consisting of abasic nucleotides, inverted abasic nucleotides, inverted deoxyribonucleotides, 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs, and deoxyribonucleotides, and these N A One or more of the nucleotides may be complementary to nucleotides in the antisense strand;

[0086] y is an integer from 0 to 4, provided that when y is 1, 2, 3, or 4, one or more n nucleotides are modified or unmodified overhang nucleotides that do not base pair with nucleotides in the antisense strand; and

[0087] z is an integer from 0 to 4, provided that when z is 1, 2, 3, or 4, these N BOne or more of the nucleotides are modified nucleotides independently selected from the group consisting of 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs and deoxyribonucleotides, and when N A When nucleotides are present in the sense strand, these N B One or more of the nucleotides may be A Nucleotide complementarity, or these N B One or more of the nucleotides may be overhang nucleotides that do not base pair with nucleotides in the sense strand.

[0088] In some embodiments where the RNAi construct comprises a structure represented by formula (B), there is a nucleotide overhang at the 3′ end of the sense strand—that is, y is 1, 2, 3, or 4. In one such embodiment, y is 2. In embodiments where there is a 2-nucleotide overhang at the 3′ end of the sense strand (that is, y is 2), x is 0 and z is 2 or x is 1 and z is 2. In other embodiments where the RNAi construct comprises a structure represented by formula (B), the RNAi construct comprises a blunt end at the 3′ end of the sense strand and the 5′ end of the antisense strand (that is, y is 0). In such embodiments where there is no nucleotide overhang at the 3′ end of the sense strand (that is, y is 0): (i) x is 2 and z is 4, (ii) x is 3 and z is 4, (iii) x is 0 and z is 2, (iv) x is 1 and z is 2, or (v) x is 2 and z is 2. In any embodiment where x is greater than 0, N A The nucleotide (the terminal nucleotide at the 5' end of the sense strand) may be an inverted nucleotide, such as an inverted abasic nucleotide or an inverted deoxyribonucleotide.

[0089] In any of the above embodiments wherein the RNAi construct comprises a structure represented by formula (B), each N in both the sense strand and the antisense strand L can be 2'-O-methyl modified nucleotides. In this embodiment and any of the embodiments described above, N in formula (B) T It may be an inverted abasic nucleotide, an inverted deoxyribonucleotide, or a 2'-O-methyl modified nucleotide.

[0090] In some embodiments of the present invention, the RNAi construct comprises a sense strand and an antisense strand, wherein the antisense strand comprises a sequence complementary to a target gene sequence and the sense strand comprises a sequence sufficiently complementary to the sequence of the antisense strand to form a duplex region, wherein the RNAi construct comprises a structure represented by formula (C):

[0091]

[0092] in:

[0093] The top strand listed in the 5' to 3' direction is the sense strand and the bottom strand listed in the 3' to 5' direction is the antisense strand;

[0094] Each N F represents 2′-fluorine-modified nucleotides;

[0095] Each N L independently represents a modified nucleotide selected from the group consisting of 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs and deoxyribonucleotides;

[0096] Each N M independently represents a modified nucleotide selected from the group consisting of 2′-fluoro-modified nucleotides, 2′-O-methyl-modified nucleotides, 2′-O-methoxyethyl-modified nucleotides, 2′-O-alkyl-modified nucleotides, 2′-O-allyl-modified nucleotides, BNAs, and deoxyribonucleotides;

[0097] N T represents a modified nucleotide selected from the group consisting of an abasic nucleotide, an inverted abasic nucleotide, an inverted deoxyribonucleotide, a 2′-O-methyl modified nucleotide, a 2′-O-methoxyethyl modified nucleotide, a 2′-O-alkyl modified nucleotide, a 2′-O-allyl modified nucleotide, BNA, and a deoxyribonucleotide; and

[0098] x is 0 or 1 and Ab is an inverted abasic nucleotide.

[0099] In certain embodiments where the RNAi construct comprises a structure represented by Formula (C), N in the antisense strand M is a 2'-fluoro modified nucleotide. In these and other embodiments, each N M is a 2'-O-methyl modified nucleotide. In an alternative embodiment, each N M is a 2'-fluoro modified nucleotide. In some embodiments where the RNAi construct comprises a structure represented by formula (C), each N in both the sense strand and the antisense strand M All are 2′-O-methyl modified nucleotides.

[0100] In any of the above embodiments wherein the RNAi construct comprises a structure represented by formula (C), each N in both the sense strand and the antisense strand L can be 2'-O-methyl modified nucleotides. In these embodiments and any of the embodiments described above, N in formula (C) TIt can be an inverted abasic nucleotide, an inverted deoxyribonucleotide, or a 2′-O-methyl modified nucleotide. For example, in one embodiment, N T is an inverted abasic nucleotide or an inverted deoxyribonucleotide and x is 0. In another embodiment, N T is a 2'-O-methyl modified nucleotide and x is 1. In yet another embodiment, N T is an inverted abasic nucleotide or an inverted deoxyribonucleotide and x is 1.

[0101] In certain embodiments, the RNAi construct of the present invention comprises a sense strand and an antisense strand, wherein the antisense strand comprises a sequence complementary to a target gene sequence and the sense strand comprises a sequence sufficiently complementary to the sequence of the antisense strand to form a duplex region, wherein the RNAi construct comprises a structure represented by formula (D):

[0102]

[0103] in:

[0104] The top strand listed in the 5' to 3' direction is the sense strand and the bottom strand listed in the 3' to 5' direction is the antisense strand;

[0105] Each N F represents 2′-fluorine-modified nucleotides;

[0106] Each N M independently represents a modified nucleotide selected from the group consisting of 2′-fluoro-modified nucleotides, 2′-O-methyl-modified nucleotides, 2′-O-methoxyethyl-modified nucleotides, 2′-O-alkyl-modified nucleotides, 2′-O-allyl-modified nucleotides, bicyclic nucleic acids (BNAs), and deoxyribonucleotides;

[0107] Each N L independently represents a modified nucleotide selected from the group consisting of 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs and deoxyribonucleotides;

[0108] N T represents a modified nucleotide selected from the group consisting of an abasic nucleotide, an inverted abasic nucleotide, an inverted deoxyribonucleotide, a 2′-O-methyl modified nucleotide, a 2′-O-methoxyethyl modified nucleotide, a 2′-O-alkyl modified nucleotide, a 2′-O-allyl modified nucleotide, BNA and a deoxyribonucleotide;

[0109] x is an integer from 0 to 4, provided that when x is 1, 2, 3, or 4, these N AOne or more of the nucleotides are modified nucleotides independently selected from the group consisting of abasic nucleotides, inverted abasic nucleotides, inverted deoxyribonucleotides, 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs, and deoxyribonucleotides, and these N A One or more of the nucleotides may be complementary to nucleotides in the antisense strand;

[0110] y is an integer from 0 to 4, provided that when y is 1, 2, 3, or 4, one or more n nucleotides are modified or unmodified overhang nucleotides that do not base pair with nucleotides in the antisense strand; and

[0111] z is an integer from 0 to 4, provided that when z is 1, 2, 3, or 4, these N B One or more of the nucleotides are modified nucleotides independently selected from the group consisting of 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs and deoxyribonucleotides, and when N A When nucleotides are present in the sense strand, these N B One or more of the nucleotides may be A Nucleotide complementarity, or these N B One or more of the nucleotides may be overhang nucleotides that do not base pair with nucleotides in the sense strand.

[0112] In some embodiments where the RNAi construct comprises a structure represented by formula (D), there is a nucleotide overhang at the 3′ end of the sense strand—that is, y is 1, 2, 3, or 4. In one such embodiment, y is 2. In embodiments where there is a 2-nucleotide overhang at the 3′ end of the sense strand (that is, y is 2), x is 0 and z is 2 or x is 1 and z is 2. In other embodiments where the RNAi construct comprises a structure represented by formula (D), the RNAi construct comprises a blunt end at the 3′ end of the sense strand and the 5′ end of the antisense strand (that is, y is 0). In such embodiments where there is no nucleotide overhang at the 3′ end of the sense strand (that is, y is 0): (i) x is 2 and z is 4, (ii) x is 3 and z is 4, (iii) x is 0 and z is 2, (iv) x is 1 and z is 2, or (v) x is 2 and z is 2. In any embodiment where x is greater than 0, N A The nucleotide (the terminal nucleotide at the 5' end of the sense strand) may be an inverted nucleotide, such as an inverted abasic nucleotide or an inverted deoxyribonucleotide.

[0113] In certain embodiments wherein the RNAi construct comprises a structure represented by formula (D), the N at positions 4, 6, 8, 9, and 16 in the antisense strand, counted from the 5′ end M Each is a 2'-fluoro modified nucleotide and the N at positions 7 and 12 in the antisense strand counting from the 5' end M Each is a 2'-O-methyl modified nucleotide. In other embodiments, the N at positions 4 and 6 in the antisense strand counting from the 5' end M Each is a 2′-fluorine-modified nucleotide and N at positions 7 to 9 in the antisense strand counted from the 5′ end M Each is a 2'-O-methyl modified nucleotide. In still other embodiments, the N at positions 4, 6, 8, 9 and 16 in the antisense strand counted from the 5' end M Each is a 2'-O-methyl modified nucleotide and the N at positions 7 and 12 in the antisense strand counted from the 5' end M Each is a 2'-fluoro modified nucleotide. In an alternative embodiment wherein the RNAi construct comprises a structure represented by formula (D), the N at positions 4, 6, 8, 9 and 12 in the antisense strand counted from the 5' end M Each is a 2'-O-methyl modified nucleotide and the N at positions 7 and 16 in the antisense strand counted from the 5' end M In certain other embodiments wherein the RNAi construct comprises a structure represented by formula (D), the N at positions 7, 8, 9, and 12 in the antisense strand counted from the 5′ end are each a 2′-fluoro modified nucleotide. M Each is a 2'-O-methyl modified nucleotide and the N at positions 4, 6, and 16 in the antisense strand counted from the 5' end M Each is a 2'-fluoro modified nucleotide. In these and other embodiments wherein the RNAi construct comprises a structure represented by formula (D), N in the sense strand M is a 2'-fluoro modified nucleotide. In an alternative embodiment, N M It is a 2′-O-methyl modified nucleotide.

[0114] In any of the above embodiments wherein the RNAi construct comprises a structure represented by formula (D), each N in both the sense strand and the antisense strand L can be 2'-O-methyl modified nucleotides. In these embodiments and any of the embodiments described above, N in formula (D) T It may be an inverted abasic nucleotide, an inverted deoxyribonucleotide, or a 2'-O-methyl modified nucleotide.

[0115] The RNAi construct of the present invention may also include one or more modified internucleotide bonds. As used herein, the term "modified internucleotide bond" refers to a bond between nucleotides other than a natural 3' to 5' phosphodiester bond. In certain embodiments, the modified internucleotide bond is a phosphorus-containing internucleotide bond, such as a phosphotriester, an aminoalkylphosphotriester, an alkylphosphonate (e.g., methylphosphonate, 3'-alkylenephosphonate), a phosphinate, an aminophosphoramidate (e.g., 3'-aminophosphoramidate and aminoalkylphosphoramidate), a thiophosphate (P=S), a chiral thiophosphate, a dithiophosphate, a thiophosphoramidate, an alkylthiophosphonate, an alkylthiophosphotriester, and a boranephosphate. In one embodiment, the modified internucleotide bond is a 2' to 5' phosphodiester bond. In other embodiments, the modified internucleotide bond is a phosphorus-free internucleotide bond, and therefore can be referred to as a modified internucleoside bond. Such non-phosphorus-containing bonds include, but are not limited to: morpholino linkages (formed in part by the sugar portion of the nucleoside); siloxane linkages (—O—Si(H)2—O—); sulfide, sulfoxide, and sulfone linkages; formyl and thioformyl linkages; olefin-containing backbones; sulfamate backbones; methylene azomethine (—CH2—N(CH3)—O—CH2—) and methylene hydrazino linkages; sulfonate and sulfonamide linkages; amide linkages; and other linkages with mixed N, O, S, and CH2 components. In one embodiment, the modified internucleoside linkage is a peptide-based linkage (e.g., aminoethylglycine) used to form peptide nucleic acids or PNAs, as described in U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262. Other suitable modified internucleotide and internucleoside linkages that can be employed in the RNAi constructs of the invention are described in U.S. Pat. No. 6,693,187, U.S. Pat. No. 9,181,551, U.S. Pat. Publication No. 2016 / 0122761, and Deleavey and Damha, Chemistry and Biology, Vol. 19: 937-954, 2012, which are hereby incorporated by reference in their entirety.

[0116] In certain embodiments, RNAi constructs of the present invention include one or more phosphorothioate internucleotide bonds. Phosphorothioate internucleotide bonds may be present in the sense strand, antisense strand, or both strands of the RNAi construct. For example, in some embodiments, the sense strand includes 1, 2, 3, 4, 5, 6, 7, 8, or more phosphorothioate internucleotide bonds. In other embodiments, the antisense strand includes 1, 2, 3, 4, 5, 6, 7, 8, or more phosphorothioate internucleotide bonds. In still other embodiments, both strands include 1, 2, 3, 4, 5, 6, 7, 8, or more phosphorothioate internucleotide bonds. RNAi constructs can include one or more phosphorothioate internucleotide bonds at the 3'-end, 5'-end, or 3'- and 5'-ends of the sense strand, antisense strand, or both strands. For example, in certain embodiments, the RNAi construct comprises about 1 to about 6 or more (e.g., about 1, 2, 3, 4, 5, 6 or more) continuous phosphorothioate internucleotide bonds at the 3' end of the sense strand, the antisense strand, or both strands. In other embodiments, the RNAi construct comprises about 1 to about 6 or more (e.g., about 1, 2, 3, 4, 5, 6 or more) continuous phosphorothioate internucleotide bonds at the 5' end of the sense strand, the antisense strand, or both strands.

[0117] In certain embodiments, RNAi constructs are included in a single phosphorothioate internucleotide bond between the terminal nucleotides at the 3' end of the sense strand. In other embodiments, RNAi constructs are included in two continuous phosphorothioate internucleotide bonds between the terminal nucleotides at the 3' end of the sense strand. In one embodiment, RNAi constructs are included in a single phosphorothioate internucleotide bond between the terminal nucleotides at the 3' end of the sense strand and a phosphorothioate internucleotide bond between the terminal nucleotides at the 3' end of the antisense strand. In another embodiment, RNAi constructs are included in two continuous phosphorothioate internucleotide bonds (i.e., phosphorothioate internucleotide bonds at the first and second nucleotides at the 3' end of the antisense strand) between the terminal nucleotides at the 3' end of the antisense strand. In another embodiment, RNAi constructs are included in two continuous phosphorothioate internucleotide bonds between the terminal nucleotides at the 3' end and the 5' end of the antisense strand. In another embodiment, the RNAi construct comprises two continuous phosphorothioate internucleotide bonds between the terminal nucleotides of the 3' end and the 5' end of the antisense strand and two continuous phosphorothioate internucleotide bonds at the 5' end of the sense strand. In still another embodiment, the RNAi construct comprises two continuous phosphorothioate internucleotide bonds between the terminal nucleotides of the 3' end and the 5' end of the antisense strand, and comprises two continuous phosphorothioate internucleotide bonds between the terminal nucleotides of the 3' end of the sense strand. In another embodiment, the RNAi construct comprises two continuous phosphorothioate internucleotide bonds between the terminal nucleotides of the 3' end and the 5' end of the antisense strand and comprises two continuous phosphorothioate internucleotide bonds between the terminal nucleotides of the 3' end and the 5' end of the sense strand (i.e., phosphorothioate internucleotide bonds at the first and second internucleotide bonds of the 5' end and the 3' end of the antisense strand and phosphorothioate internucleotide bonds at the first and second internucleotide bonds of the 5' end and the 3' end of the sense strand). In yet another embodiment, the RNAi construct comprises two consecutive phosphorothioate internucleotide bonds between the terminal nucleotides of both the 3' and 5' ends of the antisense strand and a single phosphorothioate internucleotide bond between the terminal nucleotides of the 3' end of the sense strand. In any embodiment where one or both strands comprise one or more phosphorothioate internucleotide bonds, the remaining internucleotide bonds within the strands may be natural 3' to 5' phosphodiester bonds. For example, in some embodiments, each internucleotide bond of the sense strand and the antisense strand is selected from phosphodiester and phosphorothioate, wherein at least one internucleotide bond is a phosphorothioate.

[0118] In the embodiment where the RNAi construct comprises a nucleotide overhang, two or more unpaired nucleotides in the overhang can be connected via a phosphorothioate internucleotide bond. In certain embodiments, all unpaired nucleotides in the nucleotide overhang at the 3' end of the antisense strand and / or the sense strand are connected via a phosphorothioate internucleotide bond. In other embodiments, all unpaired nucleotides in the nucleotide overhang at the 5' end of the antisense strand and / or the sense strand are connected via a phosphorothioate internucleotide bond. In still other embodiments, all unpaired nucleotides in any nucleotide overhang are connected via a phosphorothioate internucleotide bond.

[0119] The RNAi construct of the present invention may have Figure 1 Any one of the chemical modification patterns P1 to P30 depicted in . For example, in some embodiments, the RNAi construct comprises a sense strand of 19-23 nucleotides in length and an antisense strand of 19-23 nucleotides in length, wherein the sequences of the antisense strand and the sense strand are fully complementary to each other to form a duplex region of 19-21 base pairs, wherein: the nucleotides at positions 2, 7, and 14 of the antisense strand (counted from the 5′ end) are 2′-fluorine-modified nucleotides; the nucleotides at positions of the sense strand that pair with positions 8 to 11 and 13 in the antisense strand (counted from the 5′ end) are 2′-fluorine-modified nucleotides; neither the sense strand or the antisense strand has more than 7 total 2′-fluorine-modified nucleotides; and the RNAi construct has nucleotide overhangs at the 3′ ends of the sense strand and the antisense strand.

[0120] In one embodiment, the RNAi construct comprises:

[0121] (a) Having the following justification chain:

[0122] (i) 21 nucleotides in length;

[0123] (ii) 2′-fluoro modified nucleotides at positions 7 and 9 to 12 and 2′-O-methyl modified nucleotides at positions 1 to 6, 8, and 13 to 21 (counting from the 5′ end); and

[0124] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 19 and 20 and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0125] and

[0126] (b) having an antisense strand of:

[0127] (i) 21 nucleotides in length;

[0128] (ii) 2′-fluoro modified nucleotides at positions 2, 4, 6, 7, 12 and 14 and 2′-O-methyl modified nucleotides at positions 1, 3, 5, 8 to 11, 13, and 15 to 21 (counting from the 5′ end); and

[0129] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 19 and 20, and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0130] The RNAi construct has nucleotide overhangs comprising 2 nucleotides at the 3' end of the sense strand and the 3' end of the antisense strand.

[0131] In another embodiment, the RNAi construct comprises:

[0132] (a) Having the following justification chain:

[0133] (i) 22 nucleotides in length;

[0134] (ii) an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 1; 2′-fluoro modified nucleotides at positions 8 and 10 to 13; and 2′-O-methyl modified nucleotides at positions 2 to 7, 9, and 14 to 22 (counting from the 5′ end); and

[0135] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 20 and 21 and between nucleotides at positions 21 and 22 (counting from the 5′ end);

[0136] and

[0137] (b) having an antisense strand of:

[0138] (i) 21 nucleotides in length;

[0139] (ii) 2′-fluoro modified nucleotides at positions 2, 4, 6, 7, 12 and 14 and 2′-O-methyl modified nucleotides at positions 1, 3, 5, 8 to 11, 13, and 15 to 21 (counting from the 5′ end); and

[0140] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 19 and 20, and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0141] The RNAi construct has a nucleotide overhang of 2 nucleotides at the 3' end of the sense strand and a nucleotide overhang of 1 to 2 nucleotides at the 3' end of the antisense strand.

[0142] In another embodiment, the RNAi construct comprises:

[0143] (a) Having the following justification chain:

[0144] (i) 21 nucleotides in length;

[0145] (ii) 2′-fluoro modified nucleotides at positions 7 and 9 to 12 and 2′-O-methyl modified nucleotides at positions 1 to 6, 8, and 13 to 21 (counting from the 5′ end); and

[0146] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 19 and 20 and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0147] and

[0148] (b) having an antisense strand of:

[0149] (i) 21 nucleotides in length;

[0150] (ii) 2′-fluoro modified nucleotides at positions 2, 7, 10, 12 and 14 and 2′-O-methyl modified nucleotides at positions 1, 3 to 6, 8, 9, 11, 13, and 15 to 21 (counting from the 5′ end); and

[0151] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 19 and 20, and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0152] The RNAi construct has nucleotide overhangs comprising 2 nucleotides at the 3' end of the sense strand and the 3' end of the antisense strand.

[0153] In yet another embodiment, the RNAi construct comprises:

[0154] (a) Having the following justification chain:

[0155] (i) 21 nucleotides in length;

[0156] (ii) 2′-fluoro modified nucleotides at positions 7 and 9 to 12 and 2′-O-methyl modified nucleotides at positions 1 to 6, 8, and 13 to 21 (counting from the 5′ end); and

[0157] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 19 and 20 and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0158] and

[0159] (b) having an antisense strand of:

[0160] (i) 21 nucleotides in length;

[0161] (ii) 2′-fluoro modified nucleotides at positions 2, 4, 6, 7, 10, 12, and 14 and 2′-O-methyl modified nucleotides at positions 1, 3, 5, 8, 9, 11, 13, and 15 to 21 (counting from the 5′ end); and

[0162] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 19 and 20, and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0163] The RNAi construct has nucleotide overhangs comprising 2 nucleotides at the 3' end of the sense strand and the 3' end of the antisense strand.

[0164] In another specific embodiment, the RNAi construct comprises:

[0165] (a) Having the following justification chain:

[0166] (i) 21 nucleotides in length;

[0167] (ii) 2′-fluoro modified nucleotides at positions 7 and 9 to 12 and 2′-O-methyl modified nucleotides at positions 1 to 6, 8, and 13 to 20, and an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 21 (counting from the 5′ end); and

[0168] (iii) a phosphorothioate internucleotide bond between the nucleotides at positions 20 and 21 (counting from the 5′ end);

[0169] and

[0170] (b) having an antisense strand of:

[0171] (i) 21 nucleotides in length;

[0172] (ii) 2′-fluoro modified nucleotides at positions 2, 7, 12, and 14 and 2′-O-methyl modified nucleotides at positions 1, 3 to 6, 8 to 11, 13, and 15 to 21 (counting from the 5′ end); and

[0173] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 19 and 20, and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0174] The RNAi construct has nucleotide overhangs comprising 2 nucleotides at the 3' end of the sense strand and the 3' end of the antisense strand.

[0175] In certain embodiments, the RNAi construct comprises a sense strand of 19-21 nucleotides in length and an antisense strand of 21-23 nucleotides in length, wherein the sequences of the antisense strand and the sense strand are sufficiently complementary to each other to form a duplex region of 19-21 base pairs, wherein: the nucleotides at positions 2, 7, and 14 of the antisense strand (counted from the 5′ end) are 2′-fluorine-modified nucleotides; the nucleotides at positions of the sense strand that pair with positions 8 to 11 and 13 in the antisense strand (counted from the 5′ end) are 2′-fluorine-modified nucleotides; neither the sense strand or the antisense strand has more than 7 total 2′-fluorine-modified nucleotides; and the RNAi construct has a nucleotide overhang at the 3′ end of the antisense strand and comprises a blunt end at the 5′ end of the antisense strand / the 3′ end of the sense strand.

[0176] In one embodiment, the RNAi construct comprises:

[0177] (a) Having the following justification chain:

[0178] (i) 21 nucleotides in length;

[0179] (ii) 2′-fluoro modified nucleotides at positions 9 and 11 to 14; 2′-O-methyl modified nucleotides at positions 1 to 8, 10, and 15 to 20; and an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 21 (counting from the 5′ end); and

[0180] (iii) a phosphorothioate internucleotide bond between the nucleotides at positions 20 and 21 (counting from the 5′ end);

[0181] and

[0182] (b) having an antisense strand of:

[0183] (i) 23 nucleotides in length;

[0184] (ii) 2′-fluoro modified nucleotides at positions 2, 4, 6, 7, 12 and 14 and 2′-O-methyl modified nucleotides at positions 1, 3, 5, 8 to 11, 13, and 15 to 23 (counting from the 5′ end); and

[0185] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 21 and 22, and between nucleotides at positions 22 and 23 (counting from the 5′ end);

[0186] The RNAi construct has a nucleotide overhang comprising 2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0187] In another embodiment, the RNAi construct comprises:

[0188] (a) Having the following justification chain:

[0189] (i) 22 nucleotides in length;

[0190] (ii) an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 1; 2′-fluoro modified nucleotides at positions 10 and 12 to 15; and 2′-O-methyl modified nucleotides at positions 2 to 9, 11, and 16 to 22 (counting from the 5′ end); and

[0191] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 20 and 21 and between nucleotides at positions 21 and 22 (counting from the 5′ end);

[0192] and

[0193] (b) having an antisense strand of:

[0194] (i) 23 nucleotides in length;

[0195] (ii) 2′-fluoro modified nucleotides at positions 2, 4, 6, 7, 12 and 14 and 2′-O-methyl modified nucleotides at positions 1, 3, 5, 8 to 11, 13, and 15 to 23 (counting from the 5′ end); and

[0196] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 21 and 22, and between nucleotides at positions 22 and 23 (counting from the 5′ end);

[0197] The RNAi construct has a nucleotide overhang comprising 1-2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0198] In yet another embodiment, the RNAi construct comprises:

[0199] (a) Having the following justification chain:

[0200] (i) 21 nucleotides in length;

[0201] (ii) 2′-fluoro modified nucleotides at positions 9 and 11 to 14 and 2′-O-methyl modified nucleotides at positions 1 to 8, 10, and 15 to 21 (counting from the 5′ end); and

[0202] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 19 and 20 and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0203] and

[0204] (b) having an antisense strand of:

[0205] (i) 23 nucleotides in length;

[0206] (ii) 2′-fluoro modified nucleotides at positions 2, 4, 6, 7, 12 and 14 and 2′-O-methyl modified nucleotides at positions 1, 3, 5, 8 to 11, 13, and 15 to 23 (counting from the 5′ end); and

[0207] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 21 and 22, and between nucleotides at positions 22 and 23 (counting from the 5′ end);

[0208] The RNAi construct has a nucleotide overhang comprising 2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0209] In yet another embodiment, the RNAi construct comprises:

[0210] (a) Having the following justification chain:

[0211] (i) 22 nucleotides in length;

[0212] (ii) inverted abasic nucleotides or inverted deoxyribonucleotides at positions 1 and 22; 2′-fluoro modified nucleotides at positions 10 and 12 to 15; and 2′-O-methyl modified nucleotides at positions 2 to 9, 11, and 16 to 21 (counting from the 5′ end); and

[0213] (iii) a phosphorothioate internucleotide bond between the nucleotides at positions 21 and 22;

[0214] and

[0215] (b) having an antisense strand of:

[0216] (i) 23 nucleotides in length;

[0217] (ii) 2′-fluoro modified nucleotides at positions 2, 4, 6, 7, 12 and 14 and 2′-O-methyl modified nucleotides at positions 1, 3, 5, 8 to 11, 13, and 15 to 23 (counting from the 5′ end); and

[0218] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 21 and 22, and between nucleotides at positions 22 and 23 (counting from the 5′ end);

[0219] The RNAi construct has a nucleotide overhang comprising 1-2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0220] In a specific embodiment, the RNAi construct comprises:

[0221] (a) Having the following justification chain:

[0222] (i) 19 nucleotides in length;

[0223] (ii) 2′-fluoro modified nucleotides at positions 7 and 9 to 12 and 2′-O-methyl modified nucleotides at positions 1 to 6, 8, and 13 to 19 (counting from the 5′ end); and

[0224] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 17 and 18 and between nucleotides at positions 18 and 19 (counting from the 5′ end);

[0225] and

[0226] (b) having an antisense strand of:

[0227] (i) 21 nucleotides in length;

[0228] (ii) 2′-fluoro modified nucleotides at positions 2, 4, 6, 7, 12 and 14 and 2′-O-methyl modified nucleotides at positions 1, 3, 5, 8 to 11, 13, and 15 to 21 (counting from the 5′ end); and

[0229] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 19 and 20, and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0230] The RNAi construct has a nucleotide overhang comprising 2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0231] In another specific embodiment, the RNAi construct comprises:

[0232] (a) Having the following justification chain:

[0233] (i) 19 nucleotides in length;

[0234] (ii) 2′-fluoro modified nucleotides at positions 7 and 9 to 12; 2′-O-methyl modified nucleotides at positions 1 to 6, 8, and 13 to 18; and an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 19 (counting from the 5′ end); and

[0235] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 17 and 18 and between nucleotides at positions 18 and 19 (counting from the 5′ end);

[0236] and

[0237] (b) having an antisense strand of:

[0238] (i) 21 nucleotides in length;

[0239] (ii) 2′-fluoro modified nucleotides at positions 2, 4, 6, 7, 12 and 14 and 2′-O-methyl modified nucleotides at positions 1, 3, 5, 8 to 11, 13, and 15 to 21 (counting from the 5′ end); and

[0240] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 19 and 20, and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0241] The RNAi construct has a nucleotide overhang comprising 2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0242] In another specific embodiment, the RNAi construct comprises:

[0243] (a) Having the following justification chain:

[0244] (i) 21 nucleotides in length;

[0245] (ii) 2′-fluoro modified nucleotides at positions 9 and 11 to 14; 2′-O-methyl modified nucleotides at positions 1 to 8, 10, and 15 to 20; and an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 21 (counting from the 5′ end); and

[0246] (iii) a phosphorothioate internucleotide bond between the nucleotides at positions 20 and 21 (counting from the 5′ end);

[0247] and

[0248] (b) having an antisense strand of:

[0249] (i) 23 nucleotides in length;

[0250] (ii) 2′-fluoro modified nucleotides at positions 2, 7, 12, and 14 and 2′-O-methyl modified nucleotides at positions 1, 3 to 6, 8 to 11, 13, and 15 to 23 (counting from the 5′ end); and

[0251] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 21 and 22, and between nucleotides at positions 22 and 23 (counting from the 5′ end);

[0252] The RNAi construct has a nucleotide overhang comprising 2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0253] In yet another embodiment, the RNAi construct comprises:

[0254] (a) Having the following justification chain:

[0255] (i) 22 nucleotides in length;

[0256] (ii) an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 1; 2′-fluoro modified nucleotides at positions 10 and 12 to 15; and 2′-O-methyl modified nucleotides at positions 2 to 9, 11, and 16 to 22 (counting from the 5′ end); and

[0257] (iii) phosphorothioate internucleotide bonds between the nucleotides at positions 20 and 21 and between the nucleotides at positions 21 and 22;

[0258] and

[0259] (b) having an antisense strand of:

[0260] (i) 23 nucleotides in length;

[0261] (ii) 2′-fluoro modified nucleotides at positions 2, 7, 12, and 14 and 2′-O-methyl modified nucleotides at positions 1, 3 to 6, 8 to 11, 13, and 15 to 23 (counting from the 5′ end); and

[0262] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 21 and 22, and between nucleotides at positions 22 and 23 (counting from the 5′ end);

[0263] The RNAi construct has a nucleotide overhang comprising 1-2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0264] In yet another embodiment, the RNAi construct comprises:

[0265] (a) Having the following justification chain:

[0266] (i) 21 nucleotides in length;

[0267] (ii) 2′-fluoro modified nucleotides at positions 9 and 11 to 14; 2′-O-methyl modified nucleotides at positions 1 to 8, 10, and 15 to 20; and an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 21 (counting from the 5′ end); and

[0268] (iii) a phosphorothioate internucleotide bond between the nucleotides at positions 20 and 21 (counting from the 5′ end);

[0269] and

[0270] (b) having an antisense strand of:

[0271] (i) 23 nucleotides in length;

[0272] (ii) 2′-fluoro modified nucleotides at positions 2, 4, 7, 12 and 14 and 2′-O-methyl modified nucleotides at positions 1, 3, 5, 6, 8 to 11, 13, and 15 to 23 (counting from the 5′ end); and

[0273] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 21 and 22, and between nucleotides at positions 22 and 23 (counting from the 5′ end);

[0274] The RNAi construct has a nucleotide overhang comprising 2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0275] In another specific embodiment, the RNAi construct comprises:

[0276] (a) Having the following justification chain:

[0277] (i) 21 nucleotides in length;

[0278] (ii) 2′-fluoro modified nucleotides at positions 9, 11 to 14, 17, and 19; 2′-O-methyl modified nucleotides at positions 1 to 8, 10, 15, 16, 18, and 20; and an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 21 (counting from the 5′ end); and

[0279] (iii) a phosphorothioate internucleotide bond between the nucleotides at positions 20 and 21 (counting from the 5′ end);

[0280] and

[0281] (b) having an antisense strand of:

[0282] (i) 23 nucleotides in length;

[0283] (ii) 2′-fluoro modified nucleotides at positions 2, 4, 7, 12 and 14 and 2′-O-methyl modified nucleotides at positions 1, 3, 5, 6, 8 to 11, 13, and 15 to 23 (counting from the 5′ end); and

[0284] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 21 and 22, and between nucleotides at positions 22 and 23 (counting from the 5′ end);

[0285] The RNAi construct has a nucleotide overhang comprising 2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0286] In another specific embodiment, the RNAi construct comprises:

[0287] (a) Having the following justification chain:

[0288] (i) 19 nucleotides in length;

[0289] (ii) 2′-fluoro modified nucleotides at positions 7 and 9 to 12; 2′-O-methyl modified nucleotides at positions 1 to 6, 8, and 13 to 18; and an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 19 (counting from the 5′ end); and

[0290] (iii) a phosphorothioate internucleotide bond between the nucleotides at positions 18 and 19 and optionally between the nucleotides at positions 17 and 18 (counting from the 5′ end);

[0291] and

[0292] (b) having an antisense strand of:

[0293] (i) 21 nucleotides in length;

[0294] (ii) 2′-fluoro modified nucleotides at positions 2, 7, 12, and 14 and 2′-O-methyl modified nucleotides at positions 1, 3 to 6, 8 to 11, 13, and 15 to 21 (counting from the 5′ end); and

[0295] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 19 and 20, and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0296] The RNAi construct has a nucleotide overhang comprising 2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0297] In another specific embodiment, the RNAi construct comprises:

[0298] (a) Having the following justification chain:

[0299] (i) 21 nucleotides in length;

[0300] (ii) 2′-fluoro modified nucleotides at positions 9 and 11 to 14; 2′-O-methyl modified nucleotides at positions 1 to 8, 10, and 15 to 20; and an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 21 (counting from the 5′ end); and

[0301] (iii) a phosphorothioate internucleotide bond between the nucleotides at positions 20 and 21 (counting from the 5′ end);

[0302] and

[0303] (b) having an antisense strand of:

[0304] (i) 23 nucleotides in length;

[0305] (ii) 2′-fluoro modified nucleotides at positions 2, 4, 6, 7, 10, 12, and 14 and 2′-O-methyl modified nucleotides at positions 1, 3, 5, 8, 9, 11, 13, and 15 to 23 (counting from the 5′ end); and

[0306] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 21 and 22, and between nucleotides at positions 22 and 23 (counting from the 5′ end);

[0307] The RNAi construct has a nucleotide overhang comprising 2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0308] In another specific embodiment, the RNAi construct comprises:

[0309] (a) Having the following justification chain:

[0310] (i) 21 nucleotides in length;

[0311] (ii) 2′-fluoro modified nucleotides at positions 9 and 11 to 14; 2′-O-methyl modified nucleotides at positions 1 to 8, 10, and 15 to 20; and an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 21 (counting from the 5′ end); and

[0312] (iii) a phosphorothioate internucleotide bond between the nucleotides at positions 20 and 21 (counting from the 5′ end);

[0313] and

[0314] (b) having an antisense strand of:

[0315] (i) 23 nucleotides in length;

[0316] (ii) 2′-fluoro modified nucleotides at positions 2, 7, 10, 12, and 14 and 2′-O-methyl modified nucleotides at positions 1, 3 to 6, 8, 9, 11, 13, and 15 to 23 (counting from the 5′ end); and

[0317] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 21 and 22, and between nucleotides at positions 22 and 23 (counting from the 5′ end);

[0318] The RNAi construct has a nucleotide overhang comprising 2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0319] In another specific embodiment, the RNAi construct comprises:

[0320] (a) Having the following justification chain:

[0321] (i) 21 nucleotides in length;

[0322] (ii) 2′-fluoro modified nucleotides at positions 9, 11 to 14, 17, and 19; 2′-O-methyl modified nucleotides at positions 1 to 8, 10, 15, 16, 18, and 20; and an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 21 (counting from the 5′ end); and

[0323] (iii) a phosphorothioate internucleotide bond between the nucleotides at positions 20 and 21 (counting from the 5′ end);

[0324] and

[0325] (b) having an antisense strand of:

[0326] (i) 23 nucleotides in length;

[0327] (ii) 2′-fluoro modified nucleotides at positions 2, 7, 10, 12, and 14 and 2′-O-methyl modified nucleotides at positions 1, 3 to 6, 8, 9, 11, 13, and 15 to 23 (counting from the 5′ end); and

[0328] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 21 and 22, and between nucleotides at positions 22 and 23 (counting from the 5′ end);

[0329] The RNAi construct has a nucleotide overhang comprising 2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0330] In another specific embodiment, the RNAi construct comprises:

[0331] (a) Having the following justification chain:

[0332] (i) 21 nucleotides in length;

[0333] (ii) 2′-fluoro modified nucleotides at positions 9 and 11 to 14; 2′-O-methyl modified nucleotides at positions 1 to 8, 10, and 15 to 20; and an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 21 (counting from the 5′ end); and

[0334] (iii) a phosphorothioate internucleotide bond between the nucleotides at positions 20 and 21 (counting from the 5′ end);

[0335] and

[0336] (b) having an antisense strand of:

[0337] (i) 23 nucleotides in length;

[0338] (ii) 2′-fluoro modified nucleotides at positions 2, 4, 7, 10, 12, and 14 and 2′-O-methyl modified nucleotides at positions 1, 3, 5, 6, 8, 9, 11, 13, and 15 to 23 (counting from the 5′ end); and

[0339] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 21 and 22, and between nucleotides at positions 22 and 23 (counting from the 5′ end);

[0340] The RNAi construct has a nucleotide overhang comprising 2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0341] In some embodiments of the present invention, the RNAi construct comprises a sense strand of 19-23 nucleotides in length and an antisense strand of 19-23 nucleotides in length, wherein the sequences of the antisense strand and the sense strand are fully complementary to each other to form a duplex region of 19-21 base pairs, wherein: the nucleotides at positions 2, 14, and 16 of the antisense strand (counted from the 5' end) are 2'-fluoro-modified nucleotides; the nucleotides at positions of the sense strand that are paired with positions 10 to 13 in the antisense strand (counted from the 5' end) are 2'-fluoro-modified nucleotides; and neither the sense strand nor the antisense strand has more than 7 total 2'-fluoro-modified nucleotides. In such embodiments, the RNAi construct has a nucleotide overhang at the 3' end of the antisense strand, and comprises a blunt end at the 5' end of the antisense strand / 3' end of the sense strand. In alternative embodiments, the RNAi construct has a nucleotide overhang at the 3' end of the sense strand and the antisense strand.

[0342] In a specific embodiment, the RNAi construct comprises:

[0343] (a) Having the following justification chain:

[0344] (i) 21 nucleotides in length;

[0345] (ii) 2′-fluoro modified nucleotides at positions 7 and 9 to 12; 2′-O-methyl modified nucleotides at positions 1 to 6, 8, and 13 to 20; and an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 21 (counting from the 5′ end); and

[0346] (iii) a phosphorothioate internucleotide bond between the nucleotides at positions 20 and 21 (counting from the 5′ end);

[0347] and

[0348] (b) having an antisense strand of:

[0349] (i) 23 nucleotides in length;

[0350] (ii) 2′-fluoro modified nucleotides at positions 2, 4, 6, 8, 9, 14 and 16 and 2′-O-methyl modified nucleotides at positions 1, 3, 5, 7, 10 to 13, 15, and 17 to 23 (counting from the 5′ end); and

[0351] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 21 and 22, and between nucleotides at positions 22 and 23 (counting from the 5′ end);

[0352] The RNAi construct has a nucleotide overhang comprising 2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0353] In another specific embodiment, the RNAi construct comprises:

[0354] (a) Having the following justification chain:

[0355] (i) 21 nucleotides in length;

[0356] (ii) 2′-fluoro modified nucleotides at positions 7 and 9 to 12; 2′-O-methyl modified nucleotides at positions 1 to 6, 8, and 13 to 20; and an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 21 (counting from the 5′ end); and

[0357] (iii) a phosphorothioate internucleotide bond between the nucleotides at positions 20 and 21 (counting from the 5′ end);

[0358] and

[0359] (b) having an antisense strand of:

[0360] (i) 23 nucleotides in length;

[0361] (ii) 2′-fluoro modified nucleotides at positions 2, 7, 14, and 16 and 2′-O-methyl modified nucleotides at positions 1, 3 to 6, 8 to 13, 15, and 17 to 23 (counting from the 5′ end); and

[0362] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 21 and 22, and between nucleotides at positions 22 and 23 (counting from the 5′ end);

[0363] The RNAi construct has a nucleotide overhang comprising 2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0364] In another specific embodiment, the RNAi construct comprises:

[0365] (a) Having the following justification chain:

[0366] (i) 21 nucleotides in length;

[0367] (ii) 2′-fluoro modified nucleotides at positions 7 and 9 to 12; 2′-O-methyl modified nucleotides at positions 1 to 6, 8, and 13 to 20; and an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 21 (counting from the 5′ end); and

[0368] (iii) a phosphorothioate internucleotide bond between the nucleotides at positions 20 and 21 (counting from the 5′ end);

[0369] and

[0370] (b) having an antisense strand of:

[0371] (i) 23 nucleotides in length;

[0372] (ii) 2′-fluoro modified nucleotides at positions 2, 4, 6, 14 and 16 and 2′-O-methyl modified nucleotides at positions 1, 3, 5, 7 to 13, 15, and 17 to 23 (counting from the 5′ end); and

[0373] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 21 and 22, and between nucleotides at positions 22 and 23 (counting from the 5′ end);

[0374] The RNAi construct has a nucleotide overhang comprising 2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0375] In another specific embodiment, the RNAi construct comprises:

[0376] (a) Having the following justification chain:

[0377] (i) 19 nucleotides in length;

[0378] (ii) 2′-fluoro modified nucleotides at positions 5 and 7 to 10; 2′-O-methyl modified nucleotides at positions 1 to 4, 6, and 11 to 18; and an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 19 (counting from the 5′ end); and

[0379] (iii) a phosphorothioate internucleotide bond between the nucleotides at positions 18 and 19 (counting from the 5′ end);

[0380] and

[0381] (b) having an antisense strand of:

[0382] (i) 21 nucleotides in length;

[0383] (ii) 2′-fluoro modified nucleotides at positions 2, 4, 6, 8, 9, 14 and 16 and 2′-O-methyl modified nucleotides at positions 1, 3, 5, 7, 10 to 13, 15, and 17 to 21 (counting from the 5′ end); and

[0384] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 19 and 20, and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0385] The RNAi construct has a nucleotide overhang comprising 2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0386] In another specific embodiment, the RNAi construct comprises:

[0387] (a) Having the following justification chain:

[0388] (i) 20 nucleotides in length;

[0389] (ii) an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 1; a 2′-fluoro modified nucleotide at positions 8 to 11; and a 2′-O-methyl modified nucleotide at positions 2 to 7 and 12 to 20 (counting from the 5′ end); and

[0390] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 18 and 19 and between nucleotides at positions 19 and 20 (counting from the 5′ end);

[0391] and

[0392] (b) having an antisense strand of:

[0393] (i) 21 nucleotides in length;

[0394] (ii) 2′-fluoro modified nucleotides at positions 2, 7, 14, and 16 and 2′-O-methyl modified nucleotides at positions 1, 3 to 6, 8 to 13, 15, and 17 to 21 (counting from the 5′ end); and

[0395] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 19 and 20, and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0396] The RNAi construct has a nucleotide overhang comprising 1-2 nucleotides at the 3' end of the antisense strand and a blunt end at the 5' end of the antisense strand.

[0397] In another embodiment, the RNAi construct comprises:

[0398] (a) Having the following justification chain:

[0399] (i) 22 nucleotides in length;

[0400] (ii) an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 1; a 2′-fluoro modified nucleotide at positions 8 to 11; and a 2′-O-methyl modified nucleotide at positions 2 to 7 and 12 to 22 (counting from the 5′ end); and

[0401] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 20 and 21 and between nucleotides at positions 21 and 22 (counting from the 5′ end);

[0402] and

[0403] (b) having an antisense strand of:

[0404] (i) 21 nucleotides in length;

[0405] (ii) 2′-fluoro modified nucleotides at positions 2, 7, 14, and 16 and 2′-O-methyl modified nucleotides at positions 1, 3 to 6, 8 to 13, 15, and 17 to 21 (counting from the 5′ end); and

[0406] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 19 and 20, and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0407] The RNAi construct has a nucleotide overhang of 2 nucleotides at the 3' end of the sense strand and a nucleotide overhang of 1 to 2 nucleotides at the 3' end of the antisense strand.

[0408] In certain embodiments of the present invention, the RNAi construct comprises a sense strand of 19-23 nucleotides in length and an antisense strand of 19-23 nucleotides in length, wherein the sequences of the antisense strand and the sense strand are sufficiently complementary to each other to form a duplex region of 19-21 base pairs, wherein: the nucleotides at positions 2, 7, 12, and 14 of the antisense strand (counting from the 5′ end) are 2′-fluorine-modified nucleotides; the nucleotides at positions of the sense strand that pair with positions 10 to 13 in the antisense strand (counting from the 5′ end) are 2′-fluorine-modified nucleotides; neither the sense strand or the antisense strand has more than 7 total 2′-fluorine-modified nucleotides; and the RNAi construct has nucleotide overhangs at the 3′ ends of the sense strand and the antisense strand.

[0409] For example, in one embodiment, the RNAi construct comprises:

[0410] (a) Having the following justification chain:

[0411] (i) 21 nucleotides in length;

[0412] (ii) 2′-fluoro modified nucleotides at positions 7 to 10; and 2′-O-methyl modified nucleotides at positions 1 to 6 and 11 to 21 (counting from the 5′ end); and

[0413] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 19 and 20 and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0414] and

[0415] (b) having an antisense strand of:

[0416] (i) 21 nucleotides in length;

[0417] (ii) 2′-fluoro modified nucleotides at positions 2, 7, 12, and 14 and 2′-O-methyl modified nucleotides at positions 1, 3 to 6, 8 to 11, 13, and 15 to 21 (counting from the 5′ end); and

[0418] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 19 and 20, and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0419] The RNAi construct has a nucleotide overhang comprising 2 nucleotides at the 3' end of the sense strand and a nucleotide overhang comprising 2 nucleotides at the 3' end of the antisense strand.

[0420] In another embodiment, the RNAi construct comprises:

[0421] (a) Having the following justification chain:

[0422] (i) 22 nucleotides in length;

[0423] (ii) an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 1; a 2′-fluoro modified nucleotide at positions 8 to 11; and a 2′-O-methyl modified nucleotide at positions 2 to 7 and 12 to 22 (counting from the 5′ end); and

[0424] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 20 and 21 and between nucleotides at positions 21 and 22 (counting from the 5′ end);

[0425] and

[0426] (b) having an antisense strand of:

[0427] (i) 21 nucleotides in length;

[0428] (ii) 2′-fluoro modified nucleotides at positions 2, 7, 12, and 14 and 2′-O-methyl modified nucleotides at positions 1, 3 to 6, 8 to 11, 13, and 15 to 21 (counting from the 5′ end); and

[0429] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 19 and 20, and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0430] The RNAi construct has a nucleotide overhang of 2 nucleotides at the 3' end of the sense strand and a nucleotide overhang of 1 to 2 nucleotides at the 3' end of the antisense strand.

[0431] In certain embodiments of the invention, the RNAi construct comprises a sense strand of 19-21 nucleotides in length and an antisense strand of 19-21 nucleotides in length, wherein the sequences of the antisense strand and the sense strand are sufficiently complementary to each other to form a duplex region of 19-21 base pairs, wherein: the nucleotides at positions 2, 7, 12, and 14 of the antisense strand (counted from the 5' end) are 2'-fluorine-modified nucleotides; the nucleotides at positions of the sense strand that pair with positions 10, 11, and 13 in the antisense strand (counted from the 5' end) are 2'-fluorine-modified nucleotides; and neither the sense strand nor the antisense strand has more than 7 total 2'-fluorine-modified nucleotides. In one such embodiment, the RNAi construct comprises:

[0432] (a) Having the following justification chain:

[0433] (i) 21 nucleotides in length;

[0434] (ii) 2′-fluoro modified nucleotides at positions 9 and 11 to 14; and 2′-O-methyl modified nucleotides at positions 1 to 8, 10, and 15 to 20 and an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 21; (counting from the 5′ end); and

[0435] (iii) a phosphorothioate internucleotide bond between the nucleotides at positions 20 and 21 (counting from the 5′ end);

[0436] and

[0437] (b) having an antisense strand of:

[0438] (i) 21 nucleotides in length;

[0439] (ii) 2′-fluoro modified nucleotides at positions 2, 7, 12, and 14 and 2′-O-methyl modified nucleotides at positions 1, 3 to 6, 8 to 11, 13, and 15 to 21 (counting from the 5′ end); and

[0440] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 19 and 20, and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0441] The RNAi construct has two blunt ends.

[0442] In another such embodiment, the RNAi construct comprises:

[0443] (a) Having the following justification chain:

[0444] (i) 21 nucleotides in length;

[0445] (ii) 2′-fluoro modified nucleotides at positions 9 to 12; and 2′-O-methyl modified nucleotides at positions 1 to 8 and 13 to 20 and an inverted abasic nucleotide or an inverted deoxyribonucleotide at position 21; (counting from the 5′ end); and

[0446] (iii) a phosphorothioate internucleotide bond between the nucleotides at positions 20 and 21 (counting from the 5′ end);

[0447] and

[0448] (b) having an antisense strand of:

[0449] (i) 21 nucleotides in length;

[0450] (ii) 2′-fluoro modified nucleotides at positions 2, 7, 12, and 14 and 2′-O-methyl modified nucleotides at positions 1, 3 to 6, 8 to 11, 13, and 15 to 21 (counting from the 5′ end); and

[0451] (iii) phosphorothioate internucleotide bonds between nucleotides at positions 1 and 2, between nucleotides at positions 2 and 3, between nucleotides at positions 19 and 20, and between nucleotides at positions 20 and 21 (counting from the 5′ end);

[0452] The RNAi construct has two blunt ends.

[0453] In some embodiments of the present invention, the 5' end of the sense strand, the antisense strand, or both the antisense strand and the sense strand of the RNAi construct comprises a phosphate moiety. As used herein, the term "phosphate moiety" refers to a terminal phosphate group comprising an unmodified phosphate (-O-P=O)(OH)OH) and a modified phosphate. Modified phosphates include phosphates in which one or more O and OH groups are replaced by H, O, S, N(R) or an alkyl group, wherein R is H, an amino protecting group, or an unsubstituted or substituted alkyl group. Exemplary phosphate moieties include, but are not limited to: 5'-monophosphate; 5'-diphosphate; 5'-triphosphate; 5'-guanosine cap (7-methylated or unmethylated); 5'-adenosine cap or any other modified or unmodified nucleotide cap structure; 5'-monothioate (phosphorothioate); 5'-monodithioate (phosphorodithioate); 5'-α-thiotriphosphate; 5'-γ-thiotriphosphate, 5'-phosphoramidate; 5'-vinyl phosphate; 5'-alkylphosphonates (e.g., alkyl = methyl, ethyl, isopropyl, propyl, etc.); and 5'-alkyl ether phosphonates (e.g., alkyl ether = methoxymethyl, ethoxymethyl, etc.).

[0454] The modified nucleotides that can be incorporated into the RNAi constructs of the present invention may have more than one chemical modification described herein. For example, the modified nucleotides may have modifications to ribose and modifications to nucleobases. For example, the modified nucleotides may include 2' sugar modifications (e.g., 2'-fluoro or 2'-O-methyl) and include modified bases (e.g., 5-methylcytosine or pseudouracil). In other embodiments, the modified nucleotides may include a sugar modification combined with a modification to 5' phosphate, which will form a modified internucleotide bond or internucleoside bond when the modified nucleotides are incorporated into a polynucleotide. For example, in some embodiments, the modified nucleotides may include sugar modifications, such as 2'-fluoro modifications, 2'-O-methyl modifications or bicyclic sugar modifications, and 5' thiophosphate groups. Therefore, in some embodiments, one or both chains of the RNAi constructs of the present invention include a 2' modified nucleotide or a combination of a BNA and a thiophosphate internucleotide bond. In certain embodiments, both the sense and antisense strands of the RNAi constructs of the invention comprise a combination of 2'-fluoro modified nucleotides, 2'-O-methyl modified nucleotides, and phosphorothioate internucleotide linkages.

[0455] In certain embodiments, the nucleotide at position 1 of the antisense strand in the RNAi construct counting from the 5' end may comprise A, dA, dU, U, or dT. In some embodiments, at least one of the first three base pairs in the duplex region starting from the 5' end of the antisense strand is an AU base pair. In a specific embodiment, the first base pair in the duplex region starting from the 5' end of the antisense strand is an AU base pair.

[0456] RNAi constructs of the present invention can be easily made using technology as known in the art (e.g., using conventional nucleic acid solid phase synthesis). Standard nucleotides or nucleoside precursors (e.g., phosphoramidites) can be used, on a suitable nucleic acid synthesizer, the polynucleotides of the RNAi constructs can be assembled. Automatic nucleic acid synthesizers are commercially sold by several suppliers, including DNA / RNA synthesizers from Applied Biosystems (Foster City, California), MerMade synthesizers from BioAutomation (Irving, Texas) and OligoPilot synthesizers from GE Healthcare Life Sciences (Pittsburgh, Pennsylvania). The illustrative method for synthesizing RNAi constructs of the present invention has been described in Example 1.

[0457] 2' silyl protecting groups can be used in combination with acid-labile dimethoxytrityl (DMT) at the 5' position of ribonucleosides to synthesize oligonucleotides using phosphoramidite chemistry. It is known that the final deprotection conditions will not significantly degrade the RNA product. All syntheses can be performed on a large, medium or small scale in any automatic or manual synthesizer. Synthesis can also be performed in multiple well plates, columns or slides.

[0458] The 2'-O-silyl group can be removed by exposure to fluoride ions, which can include any fluoride ion source, such as salts containing fluoride ions paired with inorganic counterions (e.g., cesium fluoride and potassium fluoride), or salts containing fluoride ions paired with organic counterions (e.g., tetraalkylammonium fluorides). In the deprotection reaction, a crown ether catalyst can be used in combination with an inorganic fluoride. A preferred fluoride ion source is tetrabutylammonium fluoride, or an aminohydrofluoride (e.g., combining aqueous HF with triethylamine in a dipolar aprotic solvent such as dimethylformamide).

[0459] The choice of protecting groups used for phosphite triesters and phosphate triesters can change the stability of the triesters to fluoride. Methyl protection of phosphate triesters or phosphite triesters can stabilize the bond to fluoride ions and improve process yields.

[0460] Because ribonucleosides have a reactive 2' hydroxyl substituent, it may be desirable to protect the reactive 2' position in the RNA with a protecting group perpendicular to the 5'-O-dimethoxytrityl protecting group (e.g., one that is stable to treatment with acid). Silyl protecting groups meet this criterion and can be easily removed in the final fluoride deprotection step, which can result in minimal RNA degradation.

[0461] In the standard phosphoramidite coupling reaction, a tetrazole catalyst can be used. Preferred catalysts include, for example, tetrazole, S-ethyl-tetrazole, benzylmercaptotetrazole, and p-nitrophenyltetrazole.

[0462] As will be appreciated by those of ordinary skill in the art, other methods of synthesizing the RNAi constructs described herein will be apparent to those of skill in the art. In addition, the various synthesis steps may be performed in an alternate sequence or order to obtain the desired compound. Other synthetic chemical transformations, protecting groups (e.g., hydroxyl, amino, etc. present on bases), and protecting group methods (protection and deprotection) useful in synthesizing the RNAi constructs described herein are known in the art and include, for example, as described in R. Larock, Comprehensive Organic Transformations VCH Press (1989); T. W. Greene and PGM Wuts, Protective Groups in Organic Synthesis 2nd ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1996). Sons (1995) and subsequent editions. Custom synthesis of RNAi constructs can also be achieved from several commercial suppliers including Dharmacon, Inc. (Lafayette, Colorado), AxoLabs GmbH (Kulmbach, Germany), and Ambion, Inc. (Foster City, California).

[0463] The RNAi constructs of the present invention may include ligands. As used herein, "ligand" refers to any compound or molecule that can interact directly or indirectly with another compound or molecule. The interaction of a ligand with another compound or molecule may cause a biological response (e.g., triggering a signal transduction cascade, inducing receptor-mediated endocytosis) or simply physical binding. The ligand may change one or more properties attached to the double-stranded RNA molecule, such as the pharmacodynamics, pharmacokinetics, binding, absorption, cellular distribution, cellular uptake, charge and / or clearance properties of the RNA molecule.

[0464] Ligands may include serum proteins (e.g., human serum albumin, low-density lipoprotein, globulin), cholesterol moieties, vitamins (biotin, vitamin E, vitamin B 12 ), a folate moiety, a steroid, a bile acid (e.g., cholic acid), a fatty acid (e.g., palmitic acid, myristic acid), a carbohydrate (e.g., dextran, pullulan, chitin, chitosan, inulin, cyclodextrin, or hyaluronic acid), a glycoside, a phospholipid, or an antibody or binding fragment thereof (e.g., an antibody or binding fragment thereof that targets the RNAi construct to a specific cell type, such as the liver). Other examples of ligands include dyes, intercalating agents (e.g., acridine), cross-linking agents (e.g., psoralen, mitomycin C), porphyrins (TPPC4, Texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g., EDTA), lipophilic molecules (e.g., adamantaneacetic acid, 1-pyrenebutyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexyl, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine), peptides (e.g., Drosophila melanogaster antennapedia peptide, Tat peptide, RGD peptide), alkylating agents, polymers (e.g., polyethylene glycol (PEG) (e.g., PEG-40K)), polyamino acids, and polyamines (e.g., spermine, spermidine).

[0465] In certain embodiments, the ligand has an endosomolytic property. The endosomolytic ligand promotes the dissolution of the endosomal and / or the transport of the RNAi construct of the present invention or its components from the endosome to the cytoplasm of the cell. The endosomolytic ligand can be a polycationic peptide or peptide mimetic that exhibits pH-dependent membrane activity and fusogenicity. In one embodiment, the endosomolytic ligand presents its active conformation at endosomal pH. An "active" conformation is one in which the endosomolytic ligand promotes the dissolution of the endosomal and / or the transport of the RNAi construct of the present invention or its components from the endosome to the cytoplasm. Exemplary endosomolytic ligands include GALA peptide (Subbarao et al., Biochemistry, Vol. 26: 2964-2972, 1987), EALA peptide (Vogel et al., J. Am. Chem. Soc., Vol. 118: 1581-1586, 1996), and their derivatives (Turk et al., Biochem. Biophys. Acta, Vol. 1559: 56-68, 2002). In one embodiment, the endosomolytic component may contain chemical groups (e.g., amino acids) that will undergo changes in charge or protonation as the pH changes. The endosomolytic component may be linear or branched.

[0466] In some embodiments, the ligand comprises a lipid or other hydrophobic molecule. In one embodiment, the ligand comprises a cholesterol moiety or other steroids. It has been reported that cholesterol-conjugated oligonucleotides are more active than their unconjugated oligonucleotides (Manoharan, Antisense Nucleic Acid Drug Development, Vol. 12: 103-228, 2002). Ligands comprising cholesterol moieties and other lipids for conjugation to nucleic acid molecules have been described in U.S. Patent Nos. 7,851,615; 7,745,608; and 7,833,992, which are hereby incorporated by reference in their entirety. In another embodiment, the ligand comprises a folic acid moiety. The polynucleotides conjugated to the folic acid moiety can be taken up by cells through a receptor-mediated endocytosis pathway. Such folic acid-polynucleotide conjugates are described in U.S. Patent No. 8,188,247, which is hereby incorporated by reference in its entirety.

[0467] The ligand can target the RNAi construct to a specific tissue or cell type to selectively inhibit the expression of the target gene in the specific tissue or cell type. In one embodiment, the ligand is targeted to the specific delivery of the RNAi construct to liver cells (e.g., hepatocytes) using various methods described in more detail below. In certain embodiments, the RNAi construct is targeted to liver cells with a ligand that binds to the asialoglycoprotein receptor (ASGR) or its components (e.g., ASGR1, ASGR2) expressed on the surface.

[0468] In some embodiments, RNAi constructs can be specifically targeted to the liver by using ligands that bind or interact with proteins expressed on the surface of hepatocytes. For example, in certain embodiments, the ligand may comprise an antigen binding protein (e.g., an antibody or its binding fragment (e.g., Fab, scFv)) that specifically binds to a receptor expressed on hepatocytes (e.g., an asialoglycoprotein receptor or an LDL receptor). In a specific embodiment, the ligand comprises an antibody or its binding fragment that specifically binds to ASGR1 and / or ASGR2. In another embodiment, the ligand comprises a Fab fragment of an antibody that specifically binds to ASGR1 and / or ASGR2. "Fab fragment" consists of an immunoglobulin light chain (i.e., a light chain variable region (VL) and a constant region (CL)) and a CH1 region and a variable region (VH) of an immunoglobulin heavy chain. In another embodiment, the ligand comprises a single-chain variable antibody fragment (scFv fragment) of an antibody that specifically binds to ASGR1 and / or ASGR2. "scFv fragments" comprise the VH and VL regions of an antibody, wherein these regions are present in a single polypeptide chain, and optionally comprise a peptide linker between the VH and VL regions that enables the Fv to form a desired antigen binding structure. Exemplary antibodies and binding fragments thereof that specifically bind to ASGR1 and can be used as ligands for targeting the RNAi constructs of the present invention to the liver are described in WIPO Publication No. WO2017 / 058944, which is incorporated herein by reference in its entirety. Other antibodies and binding fragments thereof that specifically bind to ASGR1, the LDL receptor, or other liver surface-expressed proteins suitable for use as ligands in the RNAi constructs of the present invention are commercially available.

[0469] In certain embodiments, the ligand comprises a carbohydrate. "Carbohydrate" refers to a compound consisting of one or more monosaccharide units (which may be linear, branched or cyclic) having at least 6 carbon atoms, wherein an oxygen, nitrogen or sulfur atom is bonded to each carbon atom. Carbohydrates include, but are not limited to, sugars (e.g., monosaccharides, disaccharides, trisaccharides, tetrasaccharides, and oligosaccharides containing about 4, 5, 6, 7, 8, or 9 monosaccharide units), and polysaccharides (such as starches, glycogen, cellulose, and polysaccharide gums). In some embodiments, the carbohydrate incorporated into the ligand is selected from pentose, hexose, or heptose monosaccharides and disaccharides and trisaccharides comprising such monosaccharide units. In other embodiments, the carbohydrate incorporated into the ligand is an amino sugar, such as galactosamine, glucosamine, N-acetylgalactosamine, and N-acetylglucosamine.

[0470] In some embodiments, the ligand includes a hexose or a hexosamine. The hexose may be selected from glucose, galactose, mannose, fucose, or fructose. The hexosamine may be selected from fructosamine, galactosamine, glucosamine, or mannosamine. In certain embodiments, the ligand includes glucose, galactose, galactosamine, or glucosamine. In one embodiment, the ligand includes glucose, glucosamine, or N-acetylglucosamine. In another embodiment, the ligand includes galactose, galactosamine, or N-acetyl-galactosamine. In a particular embodiment, the ligand includes N-acetyl-galactosamine. Ligands including glucose, galactose, and N-acetyl-galactosamine (GalNAc) are particularly effective in targeting compounds to hepatocytes because such ligands bind to ASGR expressed on the surface of hepatocytes. See, e.g., D'Souza and Devarajan, J. Control Release, Vol. 203: 126-139, 2015. Examples of GalNAc- or galactose-containing ligands that can be incorporated into the RNAi constructs of the invention are described in U.S. Patent Nos. 7,491,805; 8,106,022; and 8,877,917; U.S. Patent Publication No. 20030130186; and WIPO Publication No. WO 2013166155, which are hereby incorporated by reference in their entireties.

[0471] In certain embodiments, the ligand comprises a multivalent carbohydrate moiety. As used herein, a "multivalent carbohydrate moiety" refers to a moiety comprising two or more carbohydrate units that can independently bind or interact with other molecules. For example, a multivalent carbohydrate moiety comprises two or more binding domains, which are composed of carbohydrates that can bind to two or more different molecules or two or more different sites on the same molecule. The valence of the carbohydrate moiety represents the number of separate binding domains within the carbohydrate moiety. For example, the terms "monovalent", "divalent", "trivalent" and "tetravalent" with respect to the carbohydrate moiety refer to carbohydrate moieties having one, two, three and four binding domains, respectively. The multivalent carbohydrate moiety may comprise: a multivalent lactose moiety, a multivalent galactose moiety, a multivalent glucose moiety, a multivalent N-acetyl-galactosamine moiety, a multivalent N-acetyl-glucosamine moiety, a multivalent mannose moiety, or a multivalent fucose moiety. In some embodiments, the ligand comprises a multivalent galactose moiety. In other embodiments, the ligand comprises a multivalent N-acetyl-galactosamine moiety. In these and other embodiments, the multivalent carbohydrate moiety can be divalent, trivalent or tetravalent. In such embodiments, the multivalent carbohydrate moiety can be biantennary or triantennary. In a specific embodiment, the multivalent N-acetyl-galactosamine moiety is trivalent or tetravalent. In another specific embodiment, the multivalent galactose moiety is trivalent or tetravalent. Exemplary trivalent and tetravalent GalNAc-containing ligands for incorporation into RNAi constructs of the present invention are described in detail below.

[0472] The ligand can be directly or indirectly attached or conjugated to the RNA molecule of RNAi construct.For example, in some embodiments, the ligand is directly covalently attached to the sense strand or antisense strand of RNAi construct.In other embodiments, the ligand is covalently attached to the sense strand or antisense strand of RNAi construct via a joint.The ligand can be attached to the core base, sugar moiety or internucleotide bond of the polynucleotide (such as sense strand or antisense strand) of RNAi construct of the present invention.With the conjugation or attachment of purine core base or its derivative, it can occur in any position including the atoms inside and outside the ring.In certain embodiments, the 2 position, 6 position, 7 position or 8 position of purine core base are attached to the ligand.With the conjugation or attachment of pyrimidine core base or its derivative can also occur in any position.In certain embodiments, the 2 position, 5 position and 6 position of pyrimidine core base can be attached to the ligand.With the conjugation or attachment of the sugar moiety of nucleotide can occur at any carbon atom. The ligand can be attached to the sugar moiety of the ligand at the 2', 3' and 5' carbon atoms. The 1' position can also be attached to the ligand, such as in abasic nucleotides. Internucleotide bonds can also support ligand attachment. For phosphorus-containing bonds (e.g., phosphodiester, phosphorothioate, phosphorodithioate, phosphoamide, etc.), the ligand can be directly attached to the phosphorus atom or attached to an O, N or S atom bonded to the phosphorus atom. For amine or amide-containing internucleoside bonds (e.g., PNA), the ligand can be attached to the nitrogen atom of the amine or amide or attached to an adjacent carbon atom.

[0473] In certain embodiments, the ligand can be attached to the 3' end or 5' end of the sense strand or antisense strand. In certain embodiments, the ligand is covalently attached to the 5' end of the sense strand. In such embodiments, the ligand is attached to the 5'-terminal nucleotide of the sense strand. In these and other embodiments, the ligand is attached to the 5'-position of the 5'-terminal nucleotide of the sense strand. In an embodiment, wherein the reverse abasic nucleotide or reverse deoxyribonucleotide is the 5'-terminal nucleotide of the sense strand and is attached to the adjacent nucleotide via a 5'-5' internucleotide bond, the ligand can be attached at the 3'-position of the reverse abasic nucleotide or reverse deoxyribonucleotide. In other embodiments, the ligand is covalently attached to the 3' end of the sense strand. For example, in some embodiments, the ligand is attached to the 3'-terminal nucleotide of the sense strand. In some such embodiments, the ligand is attached to the 3'-position of the 3'-terminal nucleotide of the sense strand. In embodiments, where the reverse abasic nucleotide or reverse deoxyribonucleotide is the 3′-terminal nucleotide of the sense strand and is attached to the adjacent nucleotide via a 3′-3′ internucleotide bond, the ligand may be attached at the 5′-position of the reverse abasic nucleotide or reverse deoxyribonucleotide. In alternative embodiments, the ligand is attached near the 3′ end of the sense strand, but before one or more terminal nucleotides (i.e., before 1, 2, 3, or 4 terminal nucleotides). In some embodiments, the ligand is attached at the 2′-position of the sugar of the 3′-terminal nucleotide of the sense strand. In other embodiments, the ligand is attached at the 2′-position of the sugar of the 5′-terminal nucleotide of the sense strand.

[0474] In certain embodiments, the ligand is attached to the sense strand or antisense strand via a joint. "Joint" is an atom or group that makes the ligand covalently attached to the polynucleotide component of the RNAi construct. The joint can be a length of about 1 to about 30 atoms, a length of about 2 to about 28 atoms, a length of about 3 to about 26 atoms, a length of about 4 to about 24 atoms, a length of about 6 to about 20 atoms, a length of about 7 to about 20 atoms, a length of about 8 to about 20 atoms, a length of about 8 to about 18 atoms, a length of about 10 to about 18 atoms, and a length of about 12 to about 18 atoms. In certain embodiments, the joint may include a bifunctional linking portion, which generally includes an alkyl portion with a functional group. One of the functional groups is selected to be combined with the compound of interest (such as the sense strand or antisense strand of the RNAi construct), and another functional group is selected to be substantially combined with any selected group (such as a ligand as described herein). In certain embodiments, the joint includes a chain structure or oligomer of a repeating unit (such as ethylene glycol or an amino acid unit). Examples of functional groups typically employed in bifunctional linking moieties include, but are not limited to, electrophiles for reacting with nucleophilic groups, and nucleophiles for reacting with electrophilic groups. In some embodiments, the bifunctional linking moiety includes amino, hydroxyl, carboxylic acid, thiol, unsaturated bonds (e.g., double bonds or triple bonds), and the like.

[0475] Linkers that can be used to attach ligands to the sense or antisense strands in the RNAi constructs of the invention include, but are not limited to, pyrrolidine, 8-amino-3,6-dioxaoctanoic acid, 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid succinimidyl ester, 6-aminohexanoic acid, substituted C1-C 10 Alkyl, substituted or unsubstituted C2-C 10 alkenyl, or substituted or unsubstituted C2-C 10 Preferred substituents for such linkers include, but are not limited to, hydroxy, amino, alkoxy, carboxyl, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl, and alkynyl.

[0476] In certain embodiments, the joint is cleavable. A cleavable joint is a joint that is fully stable outside the cell, but is cleaved to release the two parts of the joint that are kept together after entering the target cell. In certain embodiments, a cleavable joint is in a target cell or under a first reference condition (for example, the first reference condition can be selected to simulate or represent the intracellular condition), than in subject's blood or under a second reference condition (for example, the second reference condition can be selected to simulate or represent the conditions present in blood or serum) cracking fast at least 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times or more, or at least 100 times.

[0477] Cleaving joints are susceptible to the effects of cleavage agents, such as pH, redox potential or the presence of degradable molecules. Typically, cleavage agents are more prevalent or found at higher levels or higher activity inside cells than in serum or blood. Examples of such degradants include: redox agents selected for specific substrates or without substrate specificity, including, for example, oxidases or reductases or reducing agents (such as thiols) present in cells that can degrade oxidative reducible cleavable joints by reduction; esterases; endosomes or agents that can form an acidic environment, for example, those that result in a pH of five or less; enzymes that hydrolyze or degrade acid cleavable joints by acting as generalized acids, peptidases (which can be substrate specific) and phosphatases.

[0478] The cleavable linker may comprise a pH-sensitive moiety. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, in the range of about 7.1-7.3. Endosomes have a more acidic pH in the range of 5.5-6.0, and lysosomes have a more acidic pH around 5.0. Some linkers will have a cleavable group that is cleaved at a preferred pH, thereby releasing the RNA molecule from the ligand inside the cell or into a desired cell compartment.

[0479] The joint can include a cleavable group that can be cleaved by a specific enzyme. The type of cleavable group incorporated into the joint can depend on the cell to be targeted. For example, the part of the liver can be connected to the RNA molecule via a joint comprising an ester group. Hepatocytes are rich in esterases, so compared with cell types that are not rich in esterases, the joint is more efficiently cleaved in hepatocytes. Other types of cells that are rich in esterases include cells of the lung, renal cortex and testis. When targeting is rich in cells (such as hepatocytes and synoviocytes) that are peptidase, a joint containing a peptide bond can be used.

[0480] Generally, the suitability of a candidate cleavable joint can be assessed by testing the ability of a candidate joint cracking a degradation agent (or condition). It will also be desirable to test the ability of a candidate cleavable joint to resist cracking in blood or when contacting with a non-target tissue. Therefore, the relative cracking sensitivity between the first condition and the second condition can be determined, wherein the first condition is selected as the indication of cracking in the target cell and the second condition is selected as the indication of cracking in other tissues or biofluids (for example, blood or serum). Can be evaluated in a cell-free system, cell, cell culture, organ or tissue culture or whole animal. Preliminary evaluation is performed under cell-free or culture conditions and further evaluation is performed in whole animal to confirm that it may be useful. In certain embodiments, the cracking of a useful candidate joint in a cell (or under the in vitro conditions selected for simulating intracellular conditions) is at least 2,4,10,20,50,70 or 100 times faster than in blood or serum (or under the in vitro conditions of simulating extracellular conditions).

[0481] In other embodiments, an oxidation-reducible cleavage joint is used. An oxidation-reducible cleavage joint is cleaved when reduced or oxidized. An example of a reducible cleavage group is a disulfide linking group (-SS-). In order to determine whether a candidate cleavable joint is a suitable "reducible cleavage joint" or, for example, whether it is suitable for use with a specific RNAi construct and a specific ligand, one or more methods described herein can be used. For example, by hatching with dithiothreitol (DTT) or other reducing agents known in the art that mimic the cleavage rate observed in a cell (for example, a target cell), a candidate joint can be evaluated. It is also possible to evaluate a candidate joint under conditions selected to simulate blood or serum conditions. In a specific embodiment, a candidate joint is cleaved up to 10% in blood. In other embodiments, there is a useful candidate joint in a cell (or under conditions selected to simulate intracellular conditions in vitro) degradation, compared with in blood (or under conditions selected to simulate extracellular conditions), at least 2, 4, 10, 20, 50, 70 or 100 times faster.

[0482] In yet other embodiments, a phosphate-based cleavable linker that is cleaved by an agent that degrades or hydrolyzes phosphate groups is employed to covalently attach the ligand to the sense or antisense strand of the RNAi construct. Examples of agents that hydrolyze phosphate groups in cells are enzymes, such as phosphatases in cells. Examples of phosphate-based cleavable groups are -OP(O)(ORk)-O-, -OP(S)(ORk)-O-, -OP(S)(SRk)-O-, -SP(O)(ORk)-O-, -OP(O)(ORk)-S-, -SP(O)(ORk)-S-, -OP(S)(ORk)-S-, -SP(S)(ORk)-O-, -OP(O)(Rk)-O-, -OP(S)(Rk)-O-, -SP(O)(Rk)-O-, -SP(S)(Rk)-O-, -SP(O)(Rk)-S-, and -OP(S)(Rk)-S-, where Rk can be hydrogen or alkyl. Specific embodiments include -OP(O)(OH)-O-, -OP(S)(OH)-O-, -OP(S)(SH)-O-, -SP(O)(OH)-O-, -OP(O)(OH)-S-, -SP(O)(OH)-S-, -OP(S)(OH)-S-, -SP(S)(OH)-O-, -OP(O)(H)-O-, -OP(S)(H)-O-, -SP(O)(H)-O-, -SP(S)(H)-O-, -SP(O)(H)-S-, and -OP(S)(H)-S-. Another specific embodiment is -OP(O)(OH)-O-. These candidate joints can be evaluated using methods similar to those described above.

[0483] In other embodiments, the linker may include an acid-cleavable group, which is a group that is cleaved under acidic conditions. In some embodiments, the acid-cleavable group is cleaved in an acidic environment of about pH 6.5 or lower (e.g., about 6.0, 5.5, 5.0 or lower), or is cleaved by a cleaving agent (such as an enzyme that can act as a general acid). In cells, specific low pH organelles (such as endosomes and lysosomes) can provide a cleavage environment for the acid-cleavable group. Examples of acid-cleavable linkers include, but are not limited to, hydrazones, esters, and esters of amino acids. The acid-cleavable group may have the general formula -C=NN-, C(O)O, or -OC(O). When the carbon attached to the oxygen (alkoxy) of the ester is an aryl group, a specific embodiment is a substituted alkyl or tertiary alkyl group (such as dimethyl, pentyl, or tert-butyl). These candidates can be evaluated using methods similar to those described above.

[0484] In other embodiments, the joint can include ester-based cleavable groups that are cleaved by enzymes such as esterases and amidases in cells. Examples of ester-based cleavable groups include, but are not limited to, esters of alkylene, alkenylene, and alkynylene. Ester cleavable groups have the general formula -C(O)O- or -OC(O)-. These candidate joints can be evaluated using methods similar to those described above.

[0485] In further embodiments, the linker may comprise peptide-based cleavable groups that are cleaved by enzymes such as peptidases and proteases in cells. Peptide-based cleavable groups are peptide bonds formed between amino acids to produce oligopeptides (e.g., dipeptides, tripeptides, etc.) and polypeptides. Peptide-based cleavable groups include amide groups (-C(O)NH-). Amide groups can be formed between any alkylene, alkenylene, or alkynylene groups. Peptide bonds are a special type of amide bond formed between amino acids to produce peptides and proteins. Peptide-based cleavable groups are generally limited to peptide bonds (i.e., amide bonds) formed between amino acids and proteins to produce peptides. Peptide-based cleavable linkers have the general formula -NHCHR A C(O)NHCHR B C(O)-, where R A and R B are the side chains of two adjacent amino acids. These candidates can be evaluated using methods similar to those described above.

[0486] Other types of linkers suitable for attaching ligands to the sense or antisense strands in the RNAi constructs of the invention are known in the art and may include linkers described in U.S. Pat. Nos. 7,723,509; 8,017,762; 8,828,956; 8,877,917; and 9,181,551 (all of which are hereby incorporated by reference in their entirety).

[0487] In certain embodiments, the ligand covalently attached to the sense strand or antisense strand of the RNAi construct of the present invention comprises a GalNAc moiety, such as a multivalent GalNAc moiety. In some embodiments, the multivalent GalNAc moiety is a trivalent GalNAc moiety and is attached to the 3' end of the sense strand. In other embodiments, the multivalent GalNAc moiety is a trivalent GalNAc moiety and is attached to the 5' end of the sense strand. In yet other embodiments, the multivalent GalNAc moiety is a tetravalent GalNAc moiety and is attached to the 3' end of the sense strand. In still other embodiments, the multivalent GalNAc moiety is a tetravalent GalNAc moiety and is attached to the 5' end of the sense strand.

[0488] In certain embodiments, the RNAi constructs of the invention comprise a ligand having the following structure:

[0489]

[0490] In a preferred embodiment, a ligand having this structure is covalently attached to the 5' end of the sense strand via a linker, such as a linker described herein. In one embodiment, the linker is an aminohexyl linker.

[0491] Exemplary trivalent and tetravalent GalNAc moieties and linkers that can be attached to double-stranded RNA molecules in the RNAi constructs of the invention are provided below in Structural Formulas I-IX. "Ac" in the formulas listed herein represents an acetyl group.

[0492] In one embodiment, the RNAi construct comprises a ligand and a linker having the structure of Formula I below, wherein each n is independently 1 to 3, k is 1 to 3, m is 1 or 2, j is 1 or 2, and the ligand is attached to the 3′ end of the sense strand of a double-stranded RNA molecule (represented by a solid wavy line):

[0493]

[0494] In another embodiment, the RNAi construct comprises a ligand and a linker having the structure of the following Formula II, wherein each n is independently 1 to 3, k is 1 to 3, m is 1 or 2, j is 1 or 2, and the ligand is attached to the 3′ end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line):

[0495]

[0496] In yet another embodiment, the RNAi construct comprises a ligand having a structure of Formula III below and a linker, wherein the ligand is attached to the 3′ end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line):

[0497]

[0498] In yet another embodiment, the RNAi construct comprises a ligand having the structure of Formula IV below and a linker, wherein the ligand is attached to the 3′ end of the sense strand of the double-stranded RNA molecule (represented by the solid wavy line):

[0499]

[0500] In certain embodiments, the RNAi construct comprises a ligand and a linker having a structure of Formula V below, wherein each n is independently 1 to 3, k is 1 to 3, and the ligand is attached to the 5′ end of the sense strand of a double-stranded RNA molecule (represented by a solid wavy line):

[0501]

[0502] In other embodiments, the RNAi construct comprises a ligand and a linker having the structure of Formula VI below, wherein each n is independently 1 to 3, k is 1 to 3, and the ligand is attached to the 5′ end of the sense strand of a double-stranded RNA molecule (represented by the solid wavy line):

[0503]

[0504] In a specific embodiment, the RNAi construct comprises a ligand and a linker having the structure of Formula VII below, wherein X=O or S and wherein the ligand is attached to the 5′ end of the sense strand of the double-stranded RNA molecule (represented by the curved line):

[0505]

[0506] In some embodiments, the RNAi construct comprises a ligand having the structure of Formula VIII below and a linker, wherein each n is independently 1 to 3 and attaches the ligand to the 5′ end of the sense strand of a double-stranded RNA molecule (represented by the solid wavy line):

[0507]

[0508] In certain embodiments, the RNAi construct comprises a ligand having the structure of the following Formula IX and a linker, wherein the ligand is attached to the 5′ end of the sense strand of a double-stranded RNA molecule (represented by the solid wavy line):

[0509]

[0510] The phosphorothioate bond can be replaced by a phosphodiester bond as shown in any of Formulas I-IX to covalently attach the ligand and linker to the nucleic acid strand.

[0511] The present invention also includes pharmaceutical compositions and preparations, which comprise RNAi constructs as described herein and pharmaceutically acceptable carriers, excipients and / or diluents. Such compositions and preparations can be used to reduce the expression of target genes in subjects in need. In the case of considering clinical applications, pharmaceutical compositions and preparations will be prepared in a form suitable for the intended application. Typically, this will require preparation of compositions that are substantially free of pyrogens and other impurities that may be harmful to humans or animals.

[0512] The phrase "pharmaceutically acceptable" or "pharmacologically acceptable" refers to molecular entities and compositions that do not produce adverse reactions, allergic reactions or other unfavorable reactions when administered to animals or humans. As used herein, "pharmaceutically acceptable carriers, excipients, or diluents" include acceptable solvents, buffers, solutions, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents and absorption delaying agents, etc., for the formulation of drugs (such as drugs suitable for administration to humans). The use of such media and agents for pharmaceutically active substances is well known in the art. Unless any conventional media or agents are incompatible with the RNAi constructs of the present invention, they may be considered for use in therapeutic compositions. Supplementary active ingredients may also be incorporated into the composition, as long as they do not inactivate the RNAi constructs of the composition.

[0513] The composition and method for preparing the pharmaceutical composition depend on some conditions, including but not limited to: route of administration, type and degree of the disease or disorder to be treated or dosage to be administered. In some embodiments, the pharmaceutical composition is prepared based on the expected delivery route. For example, in certain embodiments, the pharmaceutical composition is formulated for parenteral delivery. Parenteral delivery forms include: intravenous, intraarterial, subcutaneous, intrathecal, intraperitoneal or intramuscular injection or infusion. In one embodiment, the pharmaceutical composition is formulated for intravenous delivery. In such embodiments, the pharmaceutical composition may include a lipid-based delivery vehicle. In another embodiment, the pharmaceutical composition is formulated for subcutaneous delivery. In such embodiments, the pharmaceutical composition may include a targeting ligand (e.g., a ligand containing GalNAc or containing an antibody as described herein).

[0514] In some embodiments, the pharmaceutical composition comprises an effective amount of the RNAi constructs described herein. An "effective amount" is an amount sufficient to produce a beneficial or desired clinical outcome. In some embodiments, an effective amount is an amount sufficient to reduce target gene expression in a subject's specific tissue or cell type (e.g., liver or hepatocytes).

[0515] The administration of the pharmaceutical composition of the present invention can be carried out via any common route, as long as the target tissue can be reached via the route. Such routes include, but are not limited to, parenteral (e.g., subcutaneous, intramuscular, intraperitoneal or intravenous), oral, nasal, buccal, intradermal, transdermal and sublingual routes, or by direct injection into liver tissue or delivery through the portal vein. In some embodiments, the pharmaceutical composition is parenteral administration. For example, in certain embodiments, the pharmaceutical composition is intravenously administered. In other embodiments, the pharmaceutical composition is subcutaneously administered.

[0516] Colloidal dispersion systems (such as macromolecular complexes, nanocapsules, microspheres, beads) and lipid-based systems (including oil-in-water emulsions, micelles, mixed micelles and liposomes) can be used as delivery vehicles for the RNAi constructs of the present invention. Commercially available fat emulsions suitable for delivering the nucleic acids of the present invention include: (Baxter International Inc.), (Abbott Pharmaceuticals), (Hospira), (Hospira), Nutrilipid (B. Braun Medical Inc.), and other similar lipid emulsions. The preferred colloidal system for use as an in vivo delivery vehicle is a liposome (i.e., an artificial membrane vesicle). The RNAi constructs of the present invention can be encapsulated in liposomes or can form complexes with them, particularly cationic liposomes. Alternatively, the RNAi constructs of the present invention can form complexes with lipids, particularly cationic lipids. Suitable lipids and liposomes include neutral (e.g., dioleoylphosphatidylethanolamine (DOPE), dimyristoylphosphatidylcholine (DMPC) and dipalmitoylphosphatidylcholine (DPPC)), distearoylphosphatidylcholine), and negative (e.g., dimyristoylphosphatidylglycerol (DMPG), and cationic (e.g., dioleoyltetramethylaminopropyl (DOTAP) and dioleoylphosphatidylethanolamine (DOTMA)). Preparation of such colloidal dispersion systems and uses are well known in the art. Exemplary formulations are also disclosed in U.S. Pat. No. 5,981,505; U.S. Pat. No. 6,217,900; U.S. Pat. No. 6,383,512; U.S. Pat. No. 5,783,565; U.S. Pat. No. 7,202,227; U.S. Pat. No. 6,379,965; U.S. Pat. No. 6,127,170; U.S. Pat. No. 5,837,533; U.S. Pat. No. 6,747,014; and WO 03 / 093449.

[0517] In certain embodiments, RNAi constructs of the present invention are fully encapsulated in lipid formulations, for example, to form SNALP or other nucleic acid-lipid particles. As used herein, term " SNALP " refers to stable nucleic acid-lipid particles. SNALP typically contains cationic lipids, non-cationic lipids and lipids (for example, PEG-lipid conjugates) that prevent particle aggregation. SNALP is particularly useful for systemic applications because they show extended circulation life after intravenous injection, and accumulate at distal sites (for example, the site physically separated from the site of application). Nucleic acid-lipid particles typically have an average diameter of about 50nm to about 150nm, about 60nm to about 130nm, about 70nm to about 110nm or about 70nm to about 90nm, and are substantially nontoxic. In addition, when present in nucleic acid-lipid particles, nucleic acid has resistance to the degradation of nuclease in aqueous solution. Nucleic acid-lipid particles and methods for making them are disclosed, for example, in U.S. Patent Nos. 5,976,567; 5,981,501; 6,534,484; 6,586,410; 6,815,432; and PCT Publication No. WO 96 / 40964.

[0518] Pharmaceutical compositions suitable for injection include, for example, sterile aqueous solutions or dispersions, and sterile powders for the temporary preparation of sterile injectable solutions or dispersions. Typically, these preparations are sterile and fluid to the extent that they are easy to inject. The preparation should be stable under the conditions of manufacture and storage, and should prevent the contamination of microorganisms (such as bacteria and fungi). Suitable solvents or dispersion media may include, for example, water, ethanol, polyols (such as glycerol, propylene glycol, and liquid polyethylene glycol, etc.), their suitable mixtures, and vegetable oils. Appropriate fluidity can be maintained, for example, by using a coating (such as lecithin), by maintaining the required particle size in the case of a dispersion, and by using a surfactant. The prevention of microbial action can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc. In many cases, it will be more preferred to include isotonic agents (such as sugar or sodium chloride). The extended absorption of injectable compositions can be achieved by using absorption delay agents (such as aluminum monostearate and gelatin) in the composition.

[0519] Sterile injectable solutions can be prepared by incorporating the proper amount of the active compound into a solvent with any other desired ingredients (e.g., as enumerated above) and then filtering the solution under sterile conditions. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and other desired ingredients (e.g., as enumerated above). In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation include vacuum drying and freeze drying techniques which yield a powder of one or more active ingredients plus any other desired ingredients from their previously sterile filtered solutions.

[0520] The compositions of the invention can generally be formulated in neutral or salt forms. Pharmaceutically acceptable salts include, for example, acid addition salts derived from inorganic acids (e.g., hydrochloric or phosphoric acids) or organic acids (e.g., acetic, oxalic, tartaric, mandelic acids, etc.) (formed with free amino groups). Salts formed with free carboxyl groups can also be derived from inorganic bases (e.g., hydroxides of sodium, potassium, ammonium, calcium, or iron) or organic bases (e.g., isopropylamine, trimethylamine, histidine, procaine, etc.).

[0521] For example, for parenteral administration in an aqueous solution, the solution is generally buffered appropriately and the liquid diluent is first rendered isotonic, for example, with sufficient saline or glucose. Such aqueous solutions can be used for, for example, intravenous, intramuscular, subcutaneous, and intraperitoneal administration. Preferably, as known to those skilled in the art and particularly in accordance with the present disclosure, a sterile aqueous medium is used. By way of illustration, a single dose can be dissolved in 1 ml of isotonic NaCl solution, or added to 1000 ml of subcutaneous perfusion fluid, or injected at the proposed infusion site (see, e.g., “Remington's Pharmaceutical Sciences”, 15th Edition, pages 1035 - 1038 and 1570 - 1580). For human administration, the preparations should meet the sterility, pyrogenicity, general safety, and purity standards required by FDA standards. In certain embodiments, the pharmaceutical compositions of the invention comprise or consist of a sterile salt solution and the RNAi constructs described herein. In other embodiments, the pharmaceutical compositions of the invention comprise or consist of the RNAi constructs described herein and sterile water (e.g., water for injection, WFI). In still other embodiments, the pharmaceutical compositions of the invention comprise or consist of the RNAi constructs described herein and phosphate buffered saline (PBS).

[0522] In some embodiments, the pharmaceutical compositions of the present invention are packaged or stored in a device for administration. Devices for injectable formulations include, but are not limited to, injection ports, prefilled syringes, automatic syringes, injection pumps, portable syringes, and injection pens. Devices for aerosol or powder formulations include, but are not limited to, inhalers, insufflators, aspirators, and the like. Thus, the present invention includes an administration device comprising a pharmaceutical composition of the present invention for use in treating or preventing one or more diseases or disorders.

[0523] The present invention provides a method for reducing or inhibiting the expression of a target gene in a cell by contacting a cell with any RNAi construct as described herein. The cell may be in vitro or in vivo. Target gene expression may be assessed by measuring the amount or level of target mRNA, target protein, or another biomarker associated with target gene expression. Relative to target gene expression in a cell or animal not treated with an RNAi construct or treated with a control RNAi construct, the reduction of target gene expression in a cell or animal treated with the RNAi construct of the present invention may be determined. For example, in some embodiments, by (a) measuring the amount or level of target mRNA in a cell treated with the RNAi construct of the present invention, (b) measuring the amount or level of target mRNA in a cell treated with a control RNAi construct (e.g., an RNAi agent for an RNA molecule not expressed in a cell or an RNAi construct with a nonsense sequence or a missense sequence) or not treated with a construct, and (c) comparing the target mRNA level measured in (a) from the treated cell with the target mRNA level measured in (b) from the control cell to assess the reduction or inhibition of target gene expression. Prior to comparison, the target mRNA levels in treated and control cells can be normalized to the RNA levels of a control gene (e.g., 18S ribosomal RNA or a housekeeping gene). Target mRNA levels can be measured by a variety of methods, including Northern blot analysis, nuclease protection assays, fluorescence in situ hybridization (FISH), reverse transcription polymerase (RT)-PCR, real-time RT-PCR, quantitative PCR, droplet digital PCR, etc.

[0524] In other embodiments, the amount or level of target protein in cells treated with RNAi constructs of the invention is measured by (a), (b) measuring the amount or level of target mRNA in cells treated with control RNAi constructs (e.g., RNAi agents directed to RNA molecules not expressed in cells or RNAi constructs with nonsense or missense sequences) or not treated with constructs, and (c) comparing the target protein levels measured in (a) from treated cells with the target protein levels measured in (b) from control cells to assess the reduction or inhibition of target gene expression. Methods for measuring target protein levels are known to those skilled in the art and include Western blotting, immunoassays (e.g., ELISA), and flow cytometry.

[0525] The present invention also provides methods for reducing or inhibiting target gene expression in a subject in need, comprising administering to a subject any of the RNAi constructs described herein. The RNAi constructs of the present invention can be used to treat or alleviate conditions, diseases or disorders associated with abnormal target gene expression or activity, for example, overexpression of gene products causes pathological phenotypes. Exemplary target genes include, but are not limited to, LPA, PNPLA3, ASGR1, F7, F12, FXI, APOCIII, APOB, APOL1, TTR, PCSK9, SCAP, KRAS, CD274, PDCD1, C5, ALAS1, HAO1, LDHA, ANGPTL3, SERPINA1, AGT, HAMP, LECT2, EGFR, VEGF, KIF11, AT3, CTNNB1, HMGB1, HIF1A, and STAT3. Target genes can also include viral genes, such as hepatitis B and hepatitis C virus genes, human immunodeficiency virus genes, herpes virus genes, etc. In some embodiments, the target gene is a gene encoding a human microRNA (miRNA).

[0526] In certain embodiments, the RNAi construct of the present invention reduces the expression of the target gene in a cell or subject by at least 50%. In certain embodiments, the RNAi construct of the present invention reduces the expression of the target gene in a cell or subject by at least 60%, at least 65%, at least 70%, at least 75%, at least 80% or at least 85%. In other embodiments, the RNAi construct of the present invention reduces the expression of the target gene in hepatocytes by about 90% or more, such as 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more. Any method described herein and other methods known in the art can be used to measure the reduction percentage of target gene expression.

[0527] The following examples, including experiments performed and results achieved, are provided for illustrative purposes only and should not be construed as limiting the scope of the appended claims.

[0528] Examples

[0529] Example 1. In vivo activity of PNPLA3 RNAi constructs with different chemical modification patterns

[0530] To evaluate the effects of different chemical modification patterns on the in vivo efficacy of RNAi constructs, RNAi constructs targeting the patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene with various patterns of 2′-fluoro-modified nucleotides and 2′-O-methyl-modified nucleotides were synthesized and evaluated in a humanized mouse model expressing PNPLA3 as described in detail below.

[0531] RNAi constructs were synthesized using solid phase phosphoramidite chemistry. Synthesis was performed on a MerMade 12 (BioAutomation) instrument.

[0532] Material

[0533] Acetonitrile (DNA synthesis grade, AXO152-2505, EMD)

[0534] Capping reagent A (80:10:10 (v / v / v) tetrahydrofuran / dimethylpyridine / acetic anhydride, BIO221 / 4000, EMD)

[0535] Capping reagent B (16% 1-methylimidazole / tetrahydrofuran, BIO345 / 4000, EMD)

[0536] Activator solution (0.25 M 5-(ethylthio)-1H-tetrazolyl (ETT) in acetonitrile, BIO152 / 0960, EMD)

[0537] Detritylation reagent (3% dichloroacetic acid in dichloromethane, BIO830 / 4000, EMD)

[0538] Oxidizing agent (0.02 M iodine in 70:20:10 (v / v / v) tetrahydrofuran / pyridine / water, BIO420 / 4000, EMD)

[0539] Diethylamine solution (20% DEA in acetonitrile, NC0017-0505, EMD)

[0540] Thiolation Reagent (0.05 M 5-N-[(dimethylamino)methylene]amino-3H-1,2,4-dithiazole-3-thione (BIOSULII / 160K) in 40:60 (v / v) pyridine / acetonitrile)

[0541] 5′-aminohexyl linker phosphoramidite, phosphorylated phosphoramidite, 2′-deoxythymidine phosphoramidite, and 2′-methoxy and 2′-fluorophosphoramidites of adenosine, guanosine, cytosine, and uridine (Thermo Fisher Scientific) were filtered through approximately 10 mL of molecular sieves. 0.10 M in acetonitrile from JTBaker

[0542] CPG Support (Hi-Load Universal Support, 500A (BH5-3500-G1), 79.6 μmol / g, 0.126 g (10 μmol))

[0543] Ammonium hydroxide (concentrated, Gitbeck)

[0544] synthesis

[0545] Reagent solution, phosphoramidite solution and solvent are connected to MerMade12 instrument.Solid support is added to each post (4mL SPE tube with top and bottom glass frit), and post is fixed to instrument.Post is washed twice with acetonitrile.Rinse phosphoramidite and reagent solution pipeline.Use Poseidon software to open synthesis.Complete synthesis by repeating deprotection / coupling / oxidation / end-capping synthesis cycle.Especially, add detritylation reagent to remove 5'-dimethoxytrityl (DMT) protecting group in solid support.Wash solid support with acetonitrile.Add phosphoramidite and activator solution in this support, then hatch so that the nucleotide entering is coupled with free 5'-hydroxyl.Wash support with acetonitrile.Add oxidation or sulfhydrylation reagent in this support, so that triester phosphite is converted into triester phosphothioate or phosphorothioate.Add end-capping reagent A and B in this support to terminate any unreacted oligonucleotide chain.Wash support with acetonitrile. After the final reaction cycle, the resin was washed with diethylamine solution to remove the 2-cyanoethyl protecting group. The support was washed with acetonitrile and dried under vacuum.

[0546] GalNAc conjugation

[0547] The positive strand (structure shown in Formula VII below) for conjugation to a trivalent N-acetyl-galactosamine (GalNAc) moiety was prepared with a 5'-aminohexyl linker. After automated synthesis, the column was removed from the instrument and transferred to a vacuum manifold in the hood. Under vacuum filtration, the 5'-monomethoxytrityl (MMT) protecting group was removed from the solid support by continuous treatment with 2 mL aliquots of 1% trifluoroacetic acid (TFA) in dichloromethane (DCM). When the orange / yellow color was no longer observed in the eluent, the resin was washed with dichloromethane. The resin was washed with 2% diisopropylethylamine in 5 mL of N,N-dimethylformamide (DMF). In a separate vial, a solution of GalNAc3-Lys2-Ahx (67 mg, 40 μmol) in DMF (0.5 mL) was prepared with 1,1,3,3-tetramethylonium tetrafluoroborate (TATU, 12.83 mg, 40 μmol) and diisopropylethylamine (DIEA) (10.5 μL, 360 μmol). The activated coupling solution was added to the resin and the column was capped and incubated overnight at room temperature. The resin was washed with DMF, DCM, and dried under vacuum.

[0548] Lysis

[0549] Remove the synthesis column from the synthesizer or vacuum manifold. Transfer the solid support from each column to a 10 mL vial. Add 4 mL of concentrated ammonium hydroxide to the solid support. Fix the cap tightly on the bottle and heat the mixture at 55 ° C for 4 h. Move the bottle to a cooler and cool for 20 minutes before opening in the hood. Filter the mixture through an 8 mL SPE tube to remove the solid support. Rinse the vial and solid support with 1 mL of 50:50 ethanol / water.

[0550] Analysis and purification

[0551] A portion of the combined filtrate was analyzed and purified by anion exchange chromatography. The combined fractions were desalted by size exclusion chromatography and analyzed by ion pair reverse phase high performance liquid chromatography-mass spectrometry (HPLC-MS). The combined fractions were lyophilized to obtain a white amorphous powder.

[0552] Analytical Anion Exchange Chromatography (AEX):

[0553] Column: Thermo DNAPac PA200RS (4.6x 50mm, 4μm)

[0554] Instrument: Agilent 1100HPLC

[0555] Buffer A: 20 mM sodium phosphate, 10% acetonitrile, pH 8.5

[0556] Buffer B: 20 ​​mM sodium phosphate, 10% acetonitrile, pH 8.5, 1 M sodium bromide

[0557] Flow rate: 1 mL / min at 40°C

[0558] Gradient: 20%-65% B in 6.2 min

[0559] Preparative Anion Exchange Chromatography (AEX):

[0560] Column: Tosoh TSK Gel SuperQ-5PW, 21 x 150 mm, 13 μm

[0561] Instrument: Agilent 1200HPLC

[0562] Buffer A: 20 mM sodium phosphate, 10% acetonitrile, pH 8.5

[0563] Buffer B: 20 ​​mM sodium phosphate, 10% acetonitrile, pH 8.5, 1 M sodium bromide

[0564] Flow rate: 8mL / min

[0565] Injection volume: 5mL

[0566] Gradient: 35%-55% B over 20 min

[0567] Preparative Size Exclusion Chromatography (SEC):

[0568] Column: GE Hi-Prep 26 / 10

[0569] Instrument: GE AKTA Pure

[0570] Buffer: 20% ethanol in water

[0571] Flow rate: 10mL / min

[0572] Injection volume: 15 mL (using sample loading pump)

[0573] Ion-pair reversed phase (IP-RP) HPLC:

[0574] Column: Water Xbridge BEH OST C18, 2.5 μm, 2.1 x 50 mm

[0575] Instrument: Agilent 1100HPLC

[0576] Buffer A: 15.7 mM DIEA, 50 mM hexylfluoroisopropanol (HFIP) in water

[0577] Buffer B: 15.7 mM DIEA, 50 mM HFIP in 50:50 water / acetonitrile

[0578] Flow rate: 0.5mL / min

[0579] Gradient: 10%-30% B over 6 min

[0580] annealing

[0581] A small amount of sense strand and antisense strand are weighed into separate vials. An siRNA reconstitution buffer (Qiagen) or phosphate buffered saline (PBS) at a concentration of about 2 mM based on dry weight is added to the vial. Actual sample concentration (ssDNA, extinction coefficient = 33 μg / OD260) is measured on NanoDrop One. The two chains are then mixed in an equimolar ratio, and the sample is heated in an incubator at 90°C for 5 minutes and allowed to cool slowly to room temperature. Samples are analyzed by AEX. The duplex is registered and submitted for in vivo testing as described in more detail below.

[0582] Preparation of GalNAc3-Lys2-Ahx

[0583] Formula VII

[0584]

[0585] Where X = O or S. The curved line represents the point of attachment to the 5' terminal nucleotide of the sense strand of the RNAi construct.

[0586] In 50mL falcon tube, add Fmoc-Ahx-OH (1.13g, 3.19mmol) in DCM (30mL), be DIEA (2.23mL, 12.78mmol) subsequently.This solution is added in 2-Cl trityl chloride resin (3.03g, 4.79mmol) in 50mL centrifuge tube and is loaded on oscillator for 2h.Solvent is drained and by resin 17:2:1DCM / MeOH / DIEA (30ml x 2), DCM (30mL x 4) washing and drying.By using UV spectrophotometric detection at 290nm, load is determined to be 0.76mmol / g.

[0587] 3 g of supported 2-Cl trityl resin was suspended in 20% 4-methylpiperidine in DMF (20 mL) and the solvent was drained after 30 min. The process was repeated once more and the resin was washed with DMF (30 mL x 3) and DCM (30 mL x 3).

[0588] To a solution of Fmoc-Lys(ivDde)-OH (3.45 g, 6 mmol) in DMF (20 mL), TATU (1.94 g, 6 mmol) was added, followed by DIEA (1.83 mL, 10.5 mmol). The solution was then added to the above deprotected resin, and the suspension was placed on a shaker overnight. The solvent was drained and the resin was washed with DMF (30 mL x 3) and DCM (30 mL x 3).

[0589] The resin was treated with 20% 4-methylpiperidine in DMF (15 mL) and after 10 min, the solvent was drained. The process was repeated once more and the resin was washed with DMF (15 mL x 4) and DCM (15 mL x 4).

[0590] To a solution of Fmoc-Lys(Fmoc)-OH (3.54 g, 6 mmol) in DMF (20 mL) was added TATU (1.94 g, 6 mmol) followed by DIEA (1.83 mL, 10.5 mmol). The solution was then added to the above deprotected resin and the suspension was placed on an oscillator overnight. The solvent was drained and the resin was washed with DMF (30 mL x 3) and DCM (30 mL x 3).

[0591] The resin was treated with 5% hydrazine in DMF (20 mL) and after 5 min, the solvent was drained. This process was repeated four more times and the resin was washed with DMF (30 mL x 4) and DCM (30 mL x 4).

[0592] To a solution of 5-(((2R,3R,4R,5R,6R)-3-acetamido-4,5-diacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)pentanoic acid (4.47 g, 10 mmol) in DMF (40 mL) was added TATU (3.22 g, 10 mmol) and the solution was stirred for 5 min. DIEA (2.96 mL, 17 mmol) was added to the solution and the mixture was then added to the above resin. The suspension was kept at room temperature overnight and the solvent was drained. The resin was washed with DMF (3 x 30 mL) and DCM (3 x 30 mL).

[0593] The resin was treated with 1% TFA in DCM (30 mL with 3% triisopropylsilane), and after 5 min, the solvent was drained. The process was repeated three times and the filtrate was concentrated in vacuo. The residue was ground with diethyl ether (50 mL), and the suspension was filtered and dried to give a crude product. The crude product was purified by reverse phase chromatography and eluted with the 0-20% MeCN solution in water. The fractions were merged and lyophilized to give a product as a white solid.

[0594] Table 1 below depicts the position of modification in the sense and antisense sequences of each modified PNPLA3 RNAi construct. The nucleotide sequences are listed according to the following symbols: dT, dA, dG, dC = corresponding deoxyribonucleotides; a, u, g, and c = corresponding 2'-O-methyl ribonucleotides; Af, Uf, Gf, and Cf = corresponding 2'-deoxy-2'-fluoro ("2'-fluoro") ribonucleotides; Phos = terminal nucleotide has a monophosphate group at its 5' end; invAb = inverted abasic nucleotide (i.e., when at the 3' end of the chain, is attached to the adjacent nucleobase via a substitution at its 3' position). In the sequence, the insertion of "s" indicates that two adjacent nucleotides are connected via a thiophosphate diester group (e.g., a thiophosphate internucleotide bond). Unless otherwise specified, all other nucleotides are connected via a 3'-5' phosphodiester group. All RNAi constructs are conjugated to the GalNAc portion shown in Formula VII via the 5' end of the sense strand. Table 1 also lists the model name and sequence family name of each RNAi construct. Figure 1 The pattern names are schematically represented in. If an RNAi construct has the same sequence family name as another RNAi construct, then the two constructs have the same core sequence but different chemical modification patterns.

[0595] Table 1. Exemplary modified PNPLA3 RNAi constructs

[0596]

[0597]

[0598] In an initial set of experiments, thirteen different PNPLA3 RNAi constructs with different sequences were synthesized to have either a P1 chemical modification pattern or a CM1 control chemical modification pattern. siRNA molecules with a CM1 control chemical modification pattern have been reported to have effective and prolonged gene silencing effects in vivo. See Nair et al., J. Am. Chem. Soc. [American Chemical Society Journal], Vol. 136: 16958-16961, 2014. The efficacy of chemically modified RNAi constructs in inhibiting PNPLA3 gene expression was evaluated in a humanized mouse model expressing wild-type human PNPLA3 or a variant form of human PNPLA3. To create a mouse model, 1×10 50 μL of ... 12 Viral particles / animal related adenovirus (AAV; serotype AAV8 or AAV7; endotoxin-free) were injected intravenously into the tail vein of C57BL / 6NCrl male mice (Charles River Laboratories Inc.) to drive human PNPLA3, PNPLA3 rs738409 , or PNPLA3 rs738409-rs738408 Gene Expression. Mice were typically 10-12 weeks old, and each treatment group included 4 to 6 animals.

[0599] After injection of AAV-PNPLA3, PNPLA3 rs738409 , and / or PNPLA3 rs738409-rs738408 All RNAi constructs were tested in mice. At least two vehicle-treated control groups were also included: AAV empty vector and AAV-PNPLA3, PNPLA3 treated with vehicle. rs738409 , or PNPLA3 rs738409-rs738408Two weeks after AAV injection, mice were treated with a single dose of RNAi construct (0.5 mM) diluted in phosphate buffered saline (Thermo Fisher Scientific, 14190-136) (at 0.5, 1.0, 3.0 or 5.0 mg / kg animal) via subcutaneous injection. On days 8, 15, 22, 28 or 42 after RNAi construct injection, livers were collected from animals, snap-frozen in liquid nitrogen, and processed for purified RNA using a Qiagen QIACubeHT instrument (9001793) and a Qiagen RNeasy96QIACube HT kit (74171) according to the manufacturer's instructions. Samples were analyzed using the QIAxpert system (9002340). RNA was treated with RQ1 RNase-free DNase (M6101) and prepared for real-time qPCR using the Applied Biosystems TaqMan™ RNA-to-CT™ 1-Step Kit (4392653). Real-time qPCR was performed on a QuantStudio real-time PCR machine. Results were based on the relative expression of mouse Gapdh (TaqMan TM Gene expression of human PNPLA3 normalized to hs00228747_m1 and 4352932E) was determined, respectively, and presented as relative knockdown of human PNPLA3 mRNA expression compared to vehicle-treated control animals.

[0600] The results of this initial set of experiments comparing RNAi constructs with the P1 chemical modification pattern (duplex numbers 4544, 3552, 2393, 3464, 3918, 2390, 2391, 2392, 3465, 3467, 2394, 3539, and 3916) with those with the CM1 control modification pattern (duplex numbers 2118, 2119, 2125, 2120, 2121, 2124, 2370, 2371, 2122, 2368, 2369, 2123, and 3558) are shown in Figure 2 When the RNAi construct was administered subcutaneously at 5 mg / kg to a cell expressing human PNPLA3 rs738409 When mice harboring the mutant gene were injected, constructs with the P1 pattern generally reduced PNPLA3 expression to a greater extent than constructs with the CM1 pattern (regardless of sequence) when measured 8 days after injection.

[0601] Varying P1 modification patterns (to modify the length of the strand, the nature of the RNAi construct ends (i.e., overhangs versus blunt ends), and / or to include inverted abasic nucleotides at the 5′ or 3′ ends of the sense strand) were prepared and applied to RNAi constructs with the same core sequence. The improved in vivo efficacy of RNAi constructs with the novel patterns was evaluated in a humanized mouse model. Specifically, RNAi constructs with P1, P2, P3, or P4 chemical modification patterns (duplex numbers 3540, 5241, 5614, and 5615) were subcutaneously administered at a dose of 5 mg / kg to a mouse expressing human PNPLA3. rs738409 The expression level of human PNPLA3 in the liver was evaluated 15 days after administration of the RNAi construct. The results are shown in Figure 3 RNAi constructs with P2, P3, or P4 patterns produced greater average reductions in PNPLA3 expression than RNAi constructs with P1 patterns.

[0602] A further modified P3 pattern was prepared to increase the efficacy and duration of mRNA knockdown in vivo. The 2′-fluoro-modified nucleotides at positions 4 and 6 of the antisense strand counted from the 5′ end in the P3 pattern (duplex number 6191) were changed to 2′-O-methyl-modified nucleotides to produce the P9 pattern. (Duplex number 6267). An RNAi construct with a P9 pattern in which a reverse deoxyribonucleotide was used to replace a reverse abasic nucleotide at the 3′ end of the sense strand (duplex number 7320) was also synthesized. All three constructs were evaluated in the humanized mouse model described above. In animals treated with 5 mg / kg of duplex number 6267, human PNPLA3 liver expression was reduced by 97% 22 days after administration, while animals treated with 5 mg / kg of duplex number 6191 showed a 92% reduction in human PNPLA3 liver expression levels at the same time point. Duplex No. 7320 was more potent and produced a longer duration of gene knockdown than Duplex Nos. 6191 and 6267, as animals treated with 3 mg / kg of Duplex No. 7320 showed a 95% reduction in human PNPLA3 liver expression levels 28 days after administration.

[0603] The P9 model was applied to PNPLA3 RNAi constructs with two different core sequences (duplex numbers 7318, 7320, 7062, 8513, and 8709) and the in vivo efficacy was evaluated in an in vivo bioluminescence imaging assay at doses of 1 mg / kg and 3 mg / kg. For bioluminescence imaging assays, the relevant adenovirus (AAV) vector was designed to contain a mouse cytomegalovirus promoter, the complete sequence of firefly luciferase, and then a string of synthetic mRNA sequences specific to the RNAi construct to be tested, immediately downstream of the firefly luciferase stop codon. At each end, the mRNA sequence is flanked by ten additional nucleotides. The vector "PP3A (DM)" was packaged into an AAV serotype, AAVDJ8 (endotoxin-free). Before injection, PP3A (DM) was diluted to 5 × 10 in phosphate-buffered saline (Thermo Fisher Scientific, 14190-136). 11 The virus particles were injected intravenously into the tail vein of BALB / c male mice (Charles River Laboratories, Inc.). The mice were typically 10-12 weeks old and each group included n=5 animals.

[0604] Two weeks after AAV injection, mice were injected with RediJect D-luciferin bioluminescent substrate (PerkinElmer, 770504) according to the manufacturer's instructions. After 10 minutes of pulse, mice were imaged on IVIS in vivo spectral imaging system (PerkinElmer). Mice were then randomized according to the baseline total flux score from the determined region of interest covering the liver. Once randomized, mice were treated with a single dose of RNAi construct (0.5mM) (via subcutaneous injection, 1.0 or 3.0 mg per kg of body weight) diluted in phosphate buffered saline (Thermo Fisher Scientific, 14190-136) or only with phosphate buffered saline (expressed as "vehicle"). Mice were imaged weekly according to the same protocol, and the same gating constraints were used for total flux scoring. Data are expressed as total flux (photons / second, y-axis) relative to the number of weeks (x-axis) after RNAi construct injection. The reduction in total flux indicates a reduction in luciferase reporter gene expression.

[0605] The results of this experiment are presented in Figure 4A and 4B At least 3 weeks after a single dose of 1 mg / kg of the RNAi construct ( Figure 4A ) and at least 5 weeks after a single dose of 3 mg / kg ( Figure 4B ), the signal of the luciferase reporter gene from animals treated with different RNAi constructs with the P9 pattern was significantly reduced compared to the signal of vehicle-treated animals. For many RNAi constructs, a single dose of 3 mg / kg was sufficient to inhibit the expression of the luciferase reporter gene for up to 6 weeks.

[0606] These RNAi constructs (duplex numbers 7318, 7320, 7062, 8513, and 8709) were also evaluated in the humanized mouse model described above. Specifically, the RNAi constructs were administered subcutaneously at 0.5, 1, or 3 mg / kg to a mouse expressing humanized PNPLA3. rs738409-rs738408 The expression level of human PNPLA3 in the liver was evaluated by qPCR 28 or 42 days after administration of the RNAi construct. The results are expressed as relative knockdown of human PNPLA3 mRNA expression compared to vehicle-treated control animals and are shown in Table 2 below.

[0607] Table 2. In vivo efficacy of PNPLA3 RNAi constructs

[0608]

[0609]

[0610] RNAi constructs with P9 modification patterns are more effective and produce longer duration of gene knockdown than previously tested patterns. Administration of a single dose of 0.5 mg / kg of RNAi constructs resulted in a decrease in human PNPLA3 liver expression by about 50% four weeks after a single dose, while administration of a 1 mg / kg dose of constructs resulted in a decrease in human PNPLA3 liver expression by about 70% four weeks after a single dose. The 1 mg / kg dose was sufficient to maintain a decrease in PNPLA3 expression of more than 55% within six weeks after a single dose. Four weeks after a single dose, administration of a single dose of 3 mg / kg of RNAi constructs resulted in a decrease in human PNPLA3 liver expression by 90% or more. Six weeks after administration of a 3 mg / kg dose, human PNPLA3 liver expression was still reduced to about 75% or more. Improved gene knockdown efficacy and duration were observed with RNAi constructs with two different sequences, indicating that the P9 chemical modification pattern effectively stabilizes the RNAi construct (at least partially independent of the nucleobase sequence).

[0611] Next, the in vivo efficacy of the PNPLA3RNAi construct with the P9 chemical modification pattern was compared with the PNPLA3RNAi construct with one of three different control modification patterns. It has been previously reported that CM2, CM3, and CM4 modification patterns improve the metabolic stability of siRNA molecules, thereby leading to improved gene silencing efficacy and duration. See Foster et al., Molecular Therapy [Molecular Therapy], Vol. 26: 708-717, 2018. All RNAi constructs have the same core nucleotide sequence in the sense strand and the antisense strand and differ only in the chemical modification pattern. Two different constructs with the P9 modification pattern were synthesized - one with a reverse baseless at the 3' end of the sense strand (duplex numbering 7318) and one with a reverse deoxythymidine at the 3' end of the sense strand (duplex numbering 8709). RNAi constructs with one of CM2, CM3, or CM4 modification patterns were also synthesized (duplex numbers were 8103, 8104, and 8105, respectively). Each RNAi construct was then administered subcutaneously at a dose of 3 mg / kg to cells expressing humanized PNPLA3. rs738409-rs738408 The expression level of human PNPLA3 in the liver was evaluated by qPCR 28 days after administration of the RNAi construct. The results are shown in Figure 5 Of all the constructs tested, the RNAi construct with a P9 modification pattern, with an inverted abasic residue at the 3′ end of the sense strand (duplex number 7318) produced the greatest reduction in liver PNPLA3 expression. The RNAi construct with a P9 modification pattern, with an inverted deoxythymidine residue at the 3′ end of the sense strand (duplex number 8709) produced a greater reduction in liver PNPLA3 expression than the construct with a CM4 pattern (duplex number 8105) and a reduction in liver PNPLA3 expression comparable to the constructs with CM2 and CM3 patterns (duplex numbers 8103 and 8104, respectively).

[0612] In a separate set of experiments, alternative changes in the P3 modification pattern were designed and evaluated for their in vivo efficacy in a humanized PNPLA3 mouse model. Changes in the P3 pattern were applied to RNAi constructs with two different sequences. The sequences of the sense and antisense strands of each RNAi construct are shown in Table 1 and Figure 1 The modification pattern is schematically shown in FIG. The RNAi construct was subcutaneously administered at a dose of 3 mg / kg to a mouse expressing humanized PNPLA3 rs738409-rs738408The expression level of human PNPLA3 in the liver was evaluated by qPCR 28 days after administration of the RNAi constructs. The results are shown in Table 3 below. At the fourth week after a single subcutaneous injection of 3 mg / kg, all RNAi constructs produced a reduction in the liver expression of human PNPLA3 by about 90% or more.

[0613] Table 3. In vivo efficacy of PNPLA3 RNAi constructs with alternative chemical modification patterns

[0614]

[0615]

[0616] Example 2. In vivo activity of ASGR1 RNAi constructs with different chemical modification patterns

[0617] As shown in Example 1, the P1 chemical modification pattern was applied to 13 different RNAi constructs with different sequences targeting human PNPLA3 mRNA to improve the gene silencing efficacy of these constructs. In order to explore whether the P1 chemical modification pattern enhances the efficacy of RNAi constructs targeting another liver gene, RNAi constructs targeting asialoglycoprotein receptor 1 (ASGR1) mRNA were synthesized using the P1 chemical modification pattern according to the method described in Example 1. RNAi constructs with the same sequence were synthesized using the CM1 control chemical modification pattern. The sequences of the RNAi constructs using the same symbols as those in Table 1 are provided in Table 4 below. The GalNAc moiety having the structure shown in Formula VII is conjugated to the 5′ end of the sense strand of the RNAi construct (designated as duplex number 1520) and the GalNAc moiety having the structure shown in Formula IX is conjugated to the 5′ end of the sense strand of the RNAi construct (designated as duplex number 1421). The conjugation of the GalNAc moiety to the sense strand of the RNAi construct is carried out as described in Example 1, except the GalNAc moiety with the structure shown in Formula IX, the GalNAc moiety is prepared as follows. To a solution of 2-(2-(2-(2-(((2R, 3R, 4R, 5R, 6R)-3-acetamido-4,5-diacetoxy-6-(acetoxymethyl) tetrahydro-2H-pyrans-2-yl)oxy)ethoxy)ethoxy)ethoxy)acetic acid (5.37g, 10mmol) in DMF (40mL), TATU (3.22g, 10mmol) is added, and the solution is stirred for 5min. DIEA (2.96mL, 17mmol) is added to the solution, and then the mixture is added to the resin described in Example 1 above. The suspension is kept at room temperature overnight and the solvent is drained. The resin is washed with DMF (3x 30mL) and DCM (3x 30mL).

[0618] Table 4. Exemplary modified ASGR1 RNAi constructs

[0619]

[0620] The in vivo efficacy of RNAi constructs in inhibiting liver mouse ASGR1 expression was evaluated by administering RNAi constructs to C57BL / 6J mice. Wild-type C57BL / 6 animals (Charles River Laboratories, Inc., Charles River) aged 10-12 weeks were fed a standard chow (2020×Teklad global extruded rodent diet without soy protein; Harlan). On day 0, mice received 5 mg / kg body weight of the specified RNAi constructs in buffer or 0.25 ml buffer (n=9 per group). Three animals were harvested on day 4, three animals on day 8, and three animals on day 15 for further analysis. Total RNA from the liver of the harvested animals was processed for qPCR analysis. The efficacy of the RNAi construct was evaluated by comparing the amount of Asgr1 mRNA in the liver tissue of animals treated with the RNAi construct with the amount of Asgr1 mRNA in the liver tissue of animals injected with buffer. The results showed that animals that received the RNAi construct with the P1 modification pattern (duplex number 1520) showed a greater reduction in hepatic ASGR1 expression than animals that received the RNAi construct with the CM1 control modification pattern at all measured time points ( Figure 6 ). Similar to the results of the RNAi construct targeting human PNPLA3 mRNA described in Example 1, the P1 chemical modification pattern improved the efficacy of the RNAi construct.

[0621] Example 3. In vivo activity of LPA RNAi constructs with different chemical modification patterns

[0622] To further evaluate the ability of the chemical modification patterns described herein to improve the in vivo efficacy of RNAi constructs, RNAi constructs targeting the third liver gene (LPA gene) were synthesized and conjugated with a GalNAc moiety having a structure shown in Formula VII according to the method described in Example 1. The sequences of the RNAi constructs using the same symbols as described above in Table 1 are provided in Table 5 below. Table 5 also lists the pattern name and sequence family name of each RNAi construct. Figure 1 The pattern names are schematically represented in. If an RNAi construct has the same sequence family name as another RNAi construct, then the two constructs have the same core sequence but different chemical modification patterns.

[0623] Table 5. Exemplary modified LPA RNAi constructs

[0624]

[0625] In initial experiments, RNAi constructs with identical nucleotide sequences were synthesized to have either a CM1 control chemical modification pattern (duplex number 3632) or a P1 chemical modification pattern (duplex number 3635). The in vivo efficacy of both constructs was evaluated in a double transgenic mouse model that expresses fully functional human Lp(a) particles with an average serum baseline Lp(a) level of approximately 50-60 mg / dL. Lp(a) is a low-density lipoprotein composed of LDL particles and the glycoprotein apolipoprotein(a) (apo(a)), which is linked to the apolipoprotein B of the LDL particles by a disulfide bond. Apo(a) is encoded by the LPA gene and changes in serum Lp(a) levels reflect changes in LPA gene expression. Double transgenic mice were generated by crossing transgenic mice expressing human apo(a) from a yeast artificial chromosome (YAC) containing the full-length human LPA gene (Frazer et al., Nature Genetics, Vol. 9: 424-431, 1995) with transgenic mice expressing human apoB-100 (Linton et al., J. Clin. Invest., Vol. 92: 3029-3037, 1993). The LPA RNAi construct was administered as a single subcutaneous injection at a dose of 0.5 mg / kg. Serum samples were taken before injection and then on days 14 and 28 after injection. The concentration of Lp(a) in serum was measured using an Lp(a) ELISA assay (Catalog No. 10-1106-01, Mercodia AB, Uppsala, Sweden). The percentage change in Lp(a) levels for each animal at a specific time point was calculated based on the animal's baseline Lp(a) levels. Results are shown in Figure 7 Two weeks after injection, administration of duplex no. 3635 having the P1 modification pattern resulted in a greater mean decrease in serum Lp(a) levels (-49%) compared to duplex no. 3632 having the control CM1 modification pattern (-35%) (although not statistically significant).

[0626] In the second series of experiments, LPA RNAi constructs targeting different regions of LPA mRNA from those in the first group of experiments were synthesized with P1 chemical modification patterns or variations of the patterns. The RNAi constructs with new patterns were evaluated in a double transgenic mouse model for the improvement of the amplitude and duration of the inhibition of LPA gene expression in vivo. In particular, LPA RNAi constructs from three different sequence families with one of the P1 modification patterns or pattern variants (e.g., P2, P4, P6, or P7 chemical modification patterns) were subcutaneously administered to the double transgenic mice described above at a dose of 2 mg / kg. The serum Lp (a) levels of animals were measured at the 1st, 2nd, and 4th weeks before injection (to obtain baseline levels) and after the LPA RNAi constructs were administered. The results of this group of experiments are shown in Table 6 below. In the three sequence families, the RNAi constructs with P2, P4, P6, or P7 modification patterns resulted in greater inhibition and duration of Lp (a) serum levels compared to the RNAi constructs with the P1 modification patterns. RNAi constructs with P6 or P7 chemical modification patterns resulted in greater than 80% reduction in serum Lp(a) levels up to 4 weeks after a single subcutaneous injection of 2 mg / kg.

[0627] Table 6. In vivo efficacy of LPA RNAi constructs

[0628]

[0629] Next, alternative changes in the chemical modification pattern were designed and evaluated for their in vivo efficacy in a double transgenic mouse model. Changes in the chemical modification pattern were applied to RNAi constructs with sequences from five different sequence families. The sequences of the sense and antisense strands of each RNAi construct are provided in Table 5 and Figure 1 The modification pattern is schematically shown in . The RNAi construct was subcutaneously administered to double transgenic mice expressing human Lp(a) particles at a dose of 1 mg / kg. The serum Lp(a) levels of the animals were measured at the 2nd, 3rd and 4th weeks before injection (to obtain baseline levels) and after administration of the LPA RNAi construct. The results are shown in Table 7 below. Four weeks after a single subcutaneous injection of 1 mg / kg, several pattern changes (such as P9, P19, P22, P24, P27, P28 and P29) caused the Lp(a) serum level to be reduced by more than 50%. The RNAi construct with the P27 chemical modification pattern is particularly effective in suppressing Lp(a) serum levels because these constructs produce a sustainable reduction of about 75% in Lp(a) levels four weeks after a single injection.

[0630] Table 7. In vivo efficacy of LPA RNAi constructs with alternative chemical modification patterns

[0631]

[0632]

[0633] All publications, patents and patent applications discussed and cited herein are incorporated herein by reference in their entirety. It should be understood that the disclosed invention is not limited to the specific methods, schemes and materials described, as these may vary. It should also be understood that the terms used herein are only for the purpose of describing specific embodiments and are not intended to limit the scope of the appended claims.

[0634] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims

1. An RNAi construct for inhibiting the expression of a target gene sequence, the RNAi construct comprising a sense strand and an antisense strand, wherein the antisense strand comprises a sequence complementary to the target gene sequence and the sense strand comprises a sequence sufficiently complementary to the sequence of the antisense strand to form a duplex region, wherein the RNAi construct comprises a structure represented by formula (A): in: The top strand listed in the 5' to 3' direction is the sense strand and the bottom strand listed in the 3' to 5' direction is the antisense strand; Each N F represents 2′-fluorine-modified nucleotides; Each N M independently represents a modified nucleotide selected from the group consisting of 2′-fluoro-modified nucleotides, 2′-O-methyl-modified nucleotides, 2′-O-methoxyethyl-modified nucleotides, 2′-O-alkyl-modified nucleotides, 2′-O-allyl-modified nucleotides, bicyclic nucleic acids (BNAs), and deoxyribonucleotides; Each N L independently represents a modified nucleotide selected from the group consisting of 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs and deoxyribonucleotides; N T represents a modified nucleotide selected from the group consisting of an abasic nucleotide, an inverted abasic nucleotide, an inverted deoxyribonucleotide, a 2′-O-methyl modified nucleotide, a 2′-O-methoxyethyl modified nucleotide, a 2′-O-alkyl modified nucleotide, a 2′-O-allyl modified nucleotide, BNA and a deoxyribonucleotide; x is an integer from 0 to 4, provided that when x is 1, 2, 3, or 4, these N A One or more of the nucleotides are modified nucleotides independently selected from the group consisting of abasic nucleotides, inverted abasic nucleotides, inverted deoxyribonucleotides, 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs, and deoxyribonucleotides, and these N A One or more of the nucleotides may be complementary to nucleotides in the antisense strand; y is an integer from 0 to 4, provided that when y is 1, 2, 3, or 4, one or more n nucleotides are modified or unmodified overhang nucleotides that do not base pair with nucleotides in the antisense strand; and z is an integer from 0 to 4, provided that when z is 1, 2, 3, or 4, these N B One or more of the nucleotides are modified nucleotides independently selected from the group consisting of 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs and deoxyribonucleotides, and when N A When nucleotides are present in the sense strand, these N B One or more of the nucleotides may be A Nucleotide complementarity, or these N B One or more of the nucleotides may be overhang nucleotides that do not base pair with nucleotides in the sense strand.

2. The RNAi construct of claim 1, wherein the sense strand and the antisense strand are each independently 19 to 30 nucleotides in length.

3. The RNAi construct of claim 1, wherein the sense strand and the antisense strand are each independently 19 to 25 nucleotides in length.

4. The RNAi construct of claim 1, wherein x is 0, y is 2, and z is 2.

5. The RNAi construct of claim 1, wherein x is 1 and N A is an inverted abasic nucleotide, y is 2, and z is 2.

6. The RNAi construct of claim 1, wherein x is 2, y is 0, and z is 4.

7. The RNAi construct of claim 1, wherein x is 2, y is 0, and z is 2.

8. The RNAi construct of claim 1, wherein x is 3 and the N at the 5′ end A is an inverted abasic nucleotide, y is 0, and z is 4.

9. The RNAi construct of claim 1, wherein x is 0, y is 0, and z is 2.

10. The RNAi construct of claim 1, wherein x is 1 and N A is an inverted abasic nucleotide, y is 0, and z is 2.

11. The RNAi construct of any one of claims 1 to 10, wherein N T It is an inverted abasic nucleotide, an inverted deoxyribonucleotide, or a 2′-O-methyl modified nucleotide.

12. The RNAi construct of any one of claims 1 to 11, wherein each N in both the sense strand and the antisense strand is L All are 2′-O-methyl modified nucleotides.

13. The RNAi construct of any one of claims 1 to 12, wherein the N at positions 4 and 12 in the antisense strand counting from the 5' end M Each is a 2'-fluorine-modified nucleotide.

14. The RNAi construct of claim 13, wherein the N at position 6 in the antisense strand counted from the 5′ end M It is a 2′-fluorine-modified nucleotide.

15. The RNAi construct of claim 14, wherein the N at position 10 in the antisense strand counted from the 5′ end M It is a 2′-fluorine-modified nucleotide.

16. The RNAi construct of any one of claims 1 to 12, wherein the N at positions 10 and 12 in the antisense strand counting from the 5′ end M Each is a 2'-fluorine-modified nucleotide.

17. The RNAi construct of claim 16, wherein the N at position 4 in the antisense strand counted from the 5′ end M It is a 2′-fluorine-modified nucleotide.

18. The RNAi construct of any one of claims 1 to 12, wherein the N at positions 4, 6 and 10 in the antisense strand counting from the 5' end M is a 2′-O-methyl modified nucleotide, and the N at position 12 in the antisense strand, counted from the 5′ end M It is a 2′-fluorine-modified nucleotide.

19. The RNAi construct of any one of claims 1 to 12, wherein each N in both the sense strand and the antisense strand is M All are 2′-O-methyl modified nucleotides.

20. The RNAi construct of any one of claims 1 to 18, wherein each N in the sense strand M It is a 2′-O-methyl modified nucleotide.

21. The RNAi construct of any one of claims 1 to 18, wherein each N in the sense strand M It is a 2′-fluorine-modified nucleotide.

22. An RNAi construct for inhibiting the expression of a target gene sequence, the RNAi construct comprising a sense strand and an antisense strand, wherein the antisense strand comprises a sequence complementary to the target gene sequence and the sense strand comprises a sequence sufficiently complementary to the sequence of the antisense strand to form a duplex region, wherein the RNAi construct comprises a structure represented by formula (B): in: The top strand listed in the 5' to 3' direction is the sense strand and the bottom strand listed in the 3' to 5' direction is the antisense strand; Each N F represents 2′-fluorine-modified nucleotides; Each N L independently represents a modified nucleotide selected from the group consisting of 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs and deoxyribonucleotides; N T represents a modified nucleotide selected from the group consisting of an abasic nucleotide, an inverted abasic nucleotide, an inverted deoxyribonucleotide, a 2′-O-methyl modified nucleotide, a 2′-O-methoxyethyl modified nucleotide, a 2′-O-alkyl modified nucleotide, a 2′-O-allyl modified nucleotide, BNA and a deoxyribonucleotide; x is an integer from 0 to 4, provided that when x is 1, 2, 3, or 4, these N A One or more of the nucleotides are modified nucleotides independently selected from the group consisting of abasic nucleotides, inverted abasic nucleotides, inverted deoxyribonucleotides, 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs, and deoxyribonucleotides, and these N A One or more of the nucleotides may be complementary to nucleotides in the antisense strand; y is an integer from 0 to 4, provided that when y is 1, 2, 3, or 4, one or more n nucleotides are modified or unmodified overhang nucleotides that do not base pair with nucleotides in the antisense strand; and z is an integer from 0 to 4, provided that when z is 1, 2, 3, or 4, these N B One or more of the nucleotides are modified nucleotides independently selected from the group consisting of 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs and deoxyribonucleotides, and when N A When nucleotides are present in the sense strand, these N B One or more of the nucleotides may be A Nucleotide complementarity, or these N B One or more of the nucleotides may be overhang nucleotides that do not base pair with nucleotides in the sense strand.

23. The RNAi construct of claim 22, wherein x is 0, y is 2, and z is 2.

24. The RNAi construct of claim 22, wherein x is 0, y is 0, and z is 2.

25. The RNAi construct of claim 22, wherein x is 1 and N A is an inverted abasic nucleotide, y is 2, and z is 2.

26. The RNAi construct of claim 22, wherein x is 2, y is 0, and z is 4.

27. The RNAi construct of claim 22, wherein x is the N at the 3 and 5' ends. A is an inverted abasic nucleotide, y is 0, and z is 4.

28. The RNAi construct of any one of claims 22 to 27, wherein N T It is an inverted abasic nucleotide, an inverted deoxyribonucleotide, or a 2′-O-methyl modified nucleotide.

29. The RNAi construct of any one of claims 22 to 28, wherein each N in both the sense strand and the antisense strand is L All are 2′-O-methyl modified nucleotides.

30. An RNAi construct for inhibiting the expression of a target gene sequence, the RNAi construct comprising a sense strand and an antisense strand, wherein the antisense strand comprises a sequence complementary to the target gene sequence and the sense strand comprises a sequence sufficiently complementary to the sequence of the antisense strand to form a duplex region, wherein the RNAi construct comprises a structure represented by formula (C): in: The top strand listed in the 5' to 3' direction is the sense strand and the bottom strand listed in the 3' to 5' direction is the antisense strand; Each N F represents 2′-fluorine-modified nucleotides; Each N L independently represents a modified nucleotide selected from the group consisting of 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs and deoxyribonucleotides; Each N M independently represents a modified nucleotide selected from the group consisting of 2′-fluoro-modified nucleotides, 2′-O-methyl-modified nucleotides, 2′-O-methoxyethyl-modified nucleotides, 2′-O-alkyl-modified nucleotides, 2′-O-allyl-modified nucleotides, BNAs, and deoxyribonucleotides; N T represents a modified nucleotide selected from the group consisting of an abasic nucleotide, an inverted abasic nucleotide, an inverted deoxyribonucleotide, a 2′-O-methyl modified nucleotide, a 2′-O-methoxyethyl modified nucleotide, a 2′-O-alkyl modified nucleotide, a 2′-O-allyl modified nucleotide, BNA, and a deoxyribonucleotide; and x is 0 or 1 and Ab is an inverted abasic nucleotide.

31. RNAi construct as claimed in claim 30, wherein each N in both the sense strand and the antisense strand M All are 2′-O-methyl modified nucleotides.

32. RNAi construct as claimed in claim 31, wherein N T is an inverted abasic nucleotide or an inverted deoxyribonucleotide and x is 0.

33. RNAi construct as claimed in claim 31, wherein N T is a 2′-O-methyl modified nucleotide and x is 1.

34. RNAi construct as claimed in claim 30, wherein the N in the antisense strand M It is a 2′-fluorine-modified nucleotide.

35. RNAi construct as claimed in claim 34, wherein each N in the sense strand M It is a 2′-O-methyl modified nucleotide.

36. RNAi construct as claimed in claim 34, wherein each N in the sense strand M It is a 2′-fluorine-modified nucleotide.

37. The RNAi construct of any one of claims 34 to 36, wherein N T is an inverted abasic nucleotide or an inverted deoxyribonucleotide and x is 0.

38. The RNAi construct of any one of claims 30 to 37, wherein each N in both the sense strand and the antisense strand is L All are 2′-O-methyl modified nucleotides.

39. An RNAi construct for inhibiting the expression of a target gene sequence, the RNAi construct comprising a sense strand and an antisense strand, wherein the antisense strand comprises a sequence complementary to the target gene sequence and the sense strand comprises a sequence sufficiently complementary to the sequence of the antisense strand to form a duplex region, wherein the RNAi construct comprises a structure represented by formula (D): in: The top strand listed in the 5' to 3' direction is the sense strand and the bottom strand listed in the 3' to 5' direction is the antisense strand; Each N F represents 2′-fluorine-modified nucleotides; Each N M independently represents a modified nucleotide selected from the group consisting of 2′-fluoro-modified nucleotides, 2′-O-methyl-modified nucleotides, 2′-O-methoxyethyl-modified nucleotides, 2′-O-alkyl-modified nucleotides, 2′-O-allyl-modified nucleotides, bicyclic nucleic acids (BNAs), and deoxyribonucleotides; Each N L independently represents a modified nucleotide selected from the group consisting of 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs and deoxyribonucleotides; N T represents a modified nucleotide selected from the group consisting of an abasic nucleotide, an inverted abasic nucleotide, an inverted deoxyribonucleotide, a 2′-O-methyl modified nucleotide, a 2′-O-methoxyethyl modified nucleotide, a 2′-O-alkyl modified nucleotide, a 2′-O-allyl modified nucleotide, BNA and a deoxyribonucleotide; x is an integer from 0 to 4, provided that when x is 1, 2, 3, or 4, these N A One or more of the nucleotides are modified nucleotides independently selected from the group consisting of abasic nucleotides, inverted abasic nucleotides, inverted deoxyribonucleotides, 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs, and deoxyribonucleotides, and these N A One or more of the nucleotides may be complementary to nucleotides in the antisense strand; y is an integer from 0 to 4, provided that when y is 1, 2, 3, or 4, one or more n nucleotides are modified or unmodified overhang nucleotides that do not base pair with nucleotides in the antisense strand; and z is an integer from 0 to 4, provided that when z is 1, 2, 3, or 4, these N B One or more of the nucleotides are modified nucleotides independently selected from the group consisting of 2′-O-methyl modified nucleotides, 2′-O-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides, 2′-O-allyl modified nucleotides, BNAs and deoxyribonucleotides, and when N A When nucleotides are present in the sense strand, these N B One or more of the nucleotides may be A Nucleotide complementarity, or these N B One or more of the nucleotides may be overhang nucleotides that do not base pair with nucleotides in the sense strand.

40. The RNAi construct of claim 39, wherein the sense strand and the antisense strand are each independently 19 to 30 nucleotides in length.

41. The RNAi construct of claim 39, wherein the sense strand and the antisense strand are each independently 19 to 25 nucleotides in length.

42. The RNAi construct of claim 39, wherein x is 2, y is 0, and z is 4.

43. RNAi construct as claimed in claim 39, wherein x is 1 and N A is an inverted abasic nucleotide, y is 2, and z is 2.

44. RNAi construct as claimed in claim 39, wherein x is 1 and N A is an inverted abasic nucleotide, y is 0, and z is 2.

45. RNAi construct as claimed in claim 39, wherein x is 0, y is 0, and z is 2.

46. ​​RNAi construct as claimed in claim 39, wherein x is 2, y is 0, and z is 2.

47. The RNAi construct of any one of claims 39 to 46, wherein N T It is an inverted abasic nucleotide, an inverted deoxyribonucleotide, or a 2′-O-methyl modified nucleotide.

48. The RNAi construct of any one of claims 39 to 47, wherein each N in the sense strand and the antisense strand is L All are 2′-O-methyl modified nucleotides.

49. The RNAi construct of any one of claims 39 to 48, wherein the N at positions 4, 6, 8, 9 and 16 in the antisense strand counting from the 5' end. M Each is a 2'-fluoro modified nucleotide and the N at positions 7 and 12 in the antisense strand counting from the 5' end M Each is a 2'-O-methyl modified nucleotide.

50. The RNAi construct of any one of claims 39 to 48, wherein the N at positions 4, 6, 8, 9 and 16 in the antisense strand counting from the 5' end M Each is a 2'-O-methyl modified nucleotide and the N at positions 7 and 12 in the antisense strand counted from the 5' end M Each is a 2'-fluorine-modified nucleotide.

51. The RNAi construct of any one of claims 39 to 48, wherein the N at positions 4, 6, 8, 9 and 12 in the antisense strand counting from the 5' end. M Each is a 2'-O-methyl modified nucleotide and the N at positions 7 and 16 in the antisense strand counted from the 5' end M Each is a 2'-fluorine-modified nucleotide.

52. The RNAi construct of any one of claims 39 to 48, wherein the N at positions 7, 8, 9 and 12 in the antisense strand counting from the 5' end. M Each is a 2'-O-methyl modified nucleotide and the N at positions 4, 6 and 16 in the antisense strand counted from the 5' end M Each is a 2'-fluorine-modified nucleotide.

53. The RNAi construct of any one of claims 39 to 52, wherein the N in the sense strand M It is a 2′-fluorine-modified nucleotide.

54. The RNAi construct of any one of claims 39 to 52, wherein the N in the sense strand M It is a 2′-O-methyl modified nucleotide.

55. The RNAi construct of any one of claims 1 to 54, wherein the sense strand, the antisense strand, or both the sense strand and the antisense strand comprise one or more phosphorothioate internucleotide bonds.

56. The RNAi construct of claim 55, wherein the antisense strand comprises two consecutive phosphorothioate internucleotide bonds between the terminal nucleotides at both the 3' end and the 5' end.

57. The RNAi construct of claim 55 or 56, wherein the sense strand comprises a single phosphorothioate internucleotide bond between the terminal nucleotides at the 3' end.

58. The RNAi construct of claim 55 or 56, wherein the sense strand comprises two consecutive phosphorothioate internucleotide bonds between the terminal nucleotides at the 3' end.

59. The RNAi construct of any one of claims 1 to 58, wherein the RNAi construct further comprises a ligand.

60. The RNAi construct of claim 59, wherein the ligand comprises a cholesterol moiety, a vitamin, a steroid, a bile acid, a folate moiety, a fatty acid, a carbohydrate, a glycoside, an antibody or an antigen-binding fragment thereof.

61. The RNAi construct of claim 59, wherein the ligand targets delivery of the RNAi construct to hepatocytes.

62. The RNAi construct of claim 59, wherein the ligand comprises galactose, galactosamine, or N-acetyl-galactosamine.

63. The RNAi construct of claim 62, wherein the ligand comprises a multivalent galactose moiety or a multivalent N-acetyl-galactosamine moiety.

64. The RNAi construct of claim 63, wherein the multivalent galactose moiety or multivalent N-acetyl-galactosamine moiety is trivalent or tetravalent.

65. The RNAi construct of any one of claims 59 to 64, wherein the ligand is covalently attached to the sense strand, optionally via a linker.

66. The RNAi construct of claim 65, wherein the ligand is covalently attached to the 5' end of the sense strand.

67. A pharmaceutical composition comprising the RNAi construct of any one of claims 1 to 66, and a pharmaceutically acceptable carrier or excipient.

68. A method for inhibiting expression of a target gene in a cell, the method comprising contacting the cell with an RNAi construct as described in any one of claims 1 to 66.

69. The method of claim 68, wherein the cell is in vivo.

70. A method for inhibiting expression of a target gene in a subject, the method comprising administering to the subject an RNAi construct as described in any one of claims 1 to 66.

71. The method of claim 70, wherein the RNAi construct is administered to the subject via a parenteral administration route.